U.S. patent application number 11/752338 was filed with the patent office on 2008-05-08 for novel method of diagnosing, monitoring, staging, imaging and treating breast cancer.
Invention is credited to Robert Cafferkey, Herve Recipon, Susana Salceda, Yongming Sun.
Application Number | 20080107596 11/752338 |
Document ID | / |
Family ID | 38196765 |
Filed Date | 2008-05-08 |
United States Patent
Application |
20080107596 |
Kind Code |
A1 |
Salceda; Susana ; et
al. |
May 8, 2008 |
Novel Method of Diagnosing, Monitoring, Staging, Imaging and
Treating Breast Cancer
Abstract
The present invention provides new markers and methods for
detecting, diagnosing, monitoring, staging, prognosticating,
imaging and treating breast cancer.
Inventors: |
Salceda; Susana; (San Jose,
CA) ; Cafferkey; Robert; (San Jose, CA) ;
Recipon; Herve; (San Francisco, CA) ; Sun;
Yongming; (San Jose, CA) |
Correspondence
Address: |
Kathleen A. Tyrrell;Licata & Tyrrell P.C.
66 E. Main Street
Marlton
NJ
08053
US
|
Family ID: |
38196765 |
Appl. No.: |
11/752338 |
Filed: |
May 23, 2007 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
09721183 |
Nov 22, 2000 |
7238471 |
|
|
11752338 |
|
|
|
|
60166973 |
Nov 23, 1999 |
|
|
|
Current U.S.
Class: |
424/1.49 ;
424/138.1; 424/178.1; 424/185.1; 424/9.34; 435/6.14; 530/350;
530/387.7; 536/23.5 |
Current CPC
Class: |
C12Q 2600/112 20130101;
A61P 43/00 20180101; G01N 33/57415 20130101; C12Q 2600/136
20130101; C12Q 1/6886 20130101 |
Class at
Publication: |
424/1.49 ;
536/23.5; 530/350; 435/6; 530/387.7; 424/9.34; 424/138.1;
424/178.1; 424/185.1 |
International
Class: |
A61K 39/395 20060101
A61K039/395; C07H 21/04 20060101 C07H021/04; C07K 14/00 20060101
C07K014/00; C12Q 1/68 20060101 C12Q001/68; A61K 39/00 20060101
A61K039/00; A61P 43/00 20060101 A61P043/00; C07K 16/18 20060101
C07K016/18; A61K 51/00 20060101 A61K051/00; A61K 49/00 20060101
A61K049/00 |
Claims
1. A BCSG comprising: (a) a polynucleotide of SEQ ID NO:1, 2, 3, 4,
5, 18 or 20 or a variant thereof; (b) a protein expressed by a
polynucleotide of SEQ ID NO:1, 2, 3, 4, 5, 18 or 20 or a variant
thereof; or (c) a polynucleotide which is capable of hybridizing
under stringent conditions to the antisense sequence of SEQ ID NO:
1, 2, 3, 4, 5, 18 or 20.
2. The BCSG of claim 1 comprising a protein of SEQ ID NO:19 or
21.
3. A method for diagnosing the presence of breast cancer in a
patient comprising: (a) determining levels of a BCSG of claim 1 in
cells, tissues or bodily fluids in a patient; and (b) comparing the
determined BCSG levels with levels of BCSG in cells, tissues or
bodily fluids from a normal human control, wherein a change in
determined levels of BCSG in said patient versus normal human
control is associated with the presence of breast cancer.
4. A method of diagnosing metastases of breast cancer in a patient
comprising: (a) identifying a patient having breast cancer that is
not known to have metastasized; (b) determining levels of a BCSG of
claim 1 in cells, tissues, or bodily fluid from said patient; and
(c) comparing the determined BCSG levels with levels of BCSG in
cells, tissue, or bodily fluid of a normal human control, wherein
an increase in determined BCSG levels in the patient versus the
normal human control is associated with breast cancer which has
metastasized.
5. A method of staging breast cancer in a patient having breast
cancer comprising: (a) identifying a patient having breast cancer;
(b) determining levels of a BCSG of claim 1 in a sample of cells,
tissue, or bodily fluid from said patient; and (c) comparing
determined BCSG levels with levels of BCSG in cells, tissues, or
bodily fluid of a normal human control, wherein an increase in
determined BCSG levels in said patient versus the normal human
control is associated with breast cancer which is progressing and a
decrease in the determined BCSG levels is associated with breast
cancer which is regressing or in remission.
6. A method of monitoring breast cancer in a patient for the onset
of metastasis comprising: (a) identifying a patient having breast
cancer that is not known to have metastasized; (b) periodically
determining levels of a BCSG of claim 1 in samples of cells,
tissues, or bodily fluid from said patient; and (c) comparing the
periodically determined BCSG levels with levels of BCSG in cells,
tissues, or bodily fluid of a normal human control, wherein an
increase in any one of the periodically determined BCSG levels in
the patient versus the normal human control is associated with
breast cancer which has metastasized.
7. A method of monitoring a change in stage of breast cancer in a
patient comprising: (a) identifying a patient having breast cancer;
(b) periodically determining levels of a BCSG of claim 1 in cells,
tissues, or bodily fluid from said patient; and (c) comparing the
periodically determined BCSG levels with levels of BCSG in cells,
tissues, or bodily fluid of a normal human control, wherein an
increase in any one of the periodically determined BCSG levels in
the patient versus the normal human control is associated with
breast cancer which is progressing in stage and a decrease is
associated with breast cancer which is regressing in stage or in
remission.
8. A method of identifying potential therapeutic agents for use in
imaging and treating breast cancer comprising screening molecules
for an ability to bind to a BCSG of claim 1 wherein the ability of
a molecule to bind to BCSG is indicative of the molecule being
useful in imaging and treating breast cancer.
9. An antibody which specifically binds a BCSG of claim 1.
10. A method of imaging breast cancer in a patient comprising
administering to the patient the antibody of claim 9.
11. The method of claim 10 wherein said antibody is labeled with
paramagnetic ions or a radioisotope.
12. A method of treating breast cancer in a patient comprising
administering to the patient the antibody of claim 9.
13. The method of claim 12 wherein the antibody is conjugated to a
cytotoxic agent.
14. A method of treating breast cancer in a patient comprising
administering to the patient a molecule which downregulates
expression or activity of a BCSG of claim 1.
15. A method of inducing an immune response against a target cell
expressing a BCSG of claim 1 comprising delivering to a human
patient an immunogenically stimulatory amount of a BCSG protein of
claim 1 so that an immune response is mounted against the target
cell.
16. A vaccine for treating breast cancer comprising a BCSG of claim
1.
Description
INTRODUCTION
[0001] This patent application is a continuation of U.S. patent
application Ser. No. 09/721,183, filed Nov. 22, 2000, which claims
the benefit of priority from U.S. Provisional Application Ser. No.
60/166,973, filed Nov. 23, 1999, teachings of each of which are
hereby incorporated by reference in their entirety.
FIELD OF THE INVENTION
[0002] This invention relates, in part, to newly identified breast
cancer specific genes and assays for detecting, diagnosing,
monitoring, staging, prognosticating, imaging and treating cancers,
particularly breast cancer.
BACKGROUND OF THE INVENTION
[0003] It is estimated that one out of every nine women in America
will develop breast cancer sometime during her life based on a
lifespan of 85 years. Annually, over 180,000 women in the United
States are diagnosed with breast cancer and approximately 46,000
die from this disease. Every woman is at risk for breast cancer.
However, a woman's chances of developing breast cancer increase as
she grows older; 80 percent of all cancers are found in women over
the age of 50. There are also several risk factors that can
increase a woman's chances of developing breast cancer. These
include a family history of breast cancer, having no children or
the first child after the age of 30, and an early start of
menstruation. However, more than 70 percent of women who develop
breast cancer have no known risk factors. Less than 10 percent of
breast cancer cases are thought to be related to the BRCA1 gene
discovered in 1994. Researchers are now investigating the role of
other factors such as nutrition, alcohol, exercise, smoking, and
oral contraceptives in development of this gynecologic cancer.
Mammograms, or special x-rays of the breast, can detect more than
90 percent of all cancers.
[0004] Procedures used for detecting, diagnosing, monitoring,
staging, and prognosticating breast cancer are of critical
importance to the outcome of the patient. Patients diagnosed early
generally have a much greater five-year survival rate as compared
to the survival rate for patients diagnosed with distant
metastasized breast cancer. New diagnostic methods which are more
sensitive and specific for detecting early breast cancer are
clearly needed.
[0005] Breast cancer patients are closely monitored following
initial therapy and during adjuvant therapy to determine response
to therapy and to detect persistent or recurrent disease or
metastasis. Thus, there is also clearly a need for cancer markers
which are more sensitive and specific in detecting breast cancer
recurrence.
[0006] Another important step in managing breast cancer is to
determine the stage of the patient's disease. Stage determination
has potential prognostic value and provides criteria for designing
optimal therapy. Generally, pathological staging of cancer is
preferable over clinical staging because the former gives a more
accurate prognosis. However, clinical staging would be preferred
were it at least as accurate as pathological staging because it
does not depend on an invasive procedure to obtain tissue for
pathological evaluation. Staging of cancer would be improved by
detecting new markers in cells, tissues or bodily fluids which
could differentiate between different stages of invasion.
[0007] New breast cancer specific genes, referred to herein as
BCSGs, have now been identified for use in diagnosing, monitoring,
staging, imaging and treating cancers, and in particular breast
cancer. Accordingly, the present invention relates to new methods
for detecting, diagnosing, monitoring, staging, prognosticating, in
vivo imaging and treating cancer via a BCSG. BCSG refers, among
other things, to native proteins expressed by the genes comprising
the polynucleotide sequences of BCSG-1 or Gene ID 332369 (SEQ ID
NO: 1), BCSG-2 or Gene ID 480489 (SEQ ID NO:2 or 18), BCSG-3 or
Gene ID 274731 (SEQ ID NO:3 or 20), BCSG-4 or Gene ID 173388 (SEQ
ID NO:4) or BCSG-5 or Clone ID 3040232, Gene ID 411152 (SEQ ID
NO:5). Exemplary proteins expressed by genes BCSG-2 and BCSG-3 are
depicted herein as SEQ ID NO:19 and SEQ ID NO:21. By "BCSG" it is
also meant herein variant polynucleotides which, due to degeneracy
in genetic coding, comprise variations in nucleotide sequence as
compared to SEQ ID NO: 1, 2, 3, 4, 5, 18 or 20 but which still
encode the same proteins. In the alternative, what is meant by BCSG
as used herein, means the native mRNAs encoded by the genes
comprising BCSG-1 or Gene ID 332369 (SEQ ID NO: 1), BCSG-2 or Gene
ID 480489 (SEQ ID NO:2 or 18), BCSG-3 or Gene ID 274731 (SEQ ID
NO:3 or 20), BCSG-4 or Gene ID 173388 (SEQ ID NO:4) or BCSG-5 or
Clone ID 3040232, Gene ID 411152 (SEQ ID NO:5) or it can refer to
the actual genes comprising BCSG-1 or Gene ID 332369 (SEQ ID NO:
1), BCSG-2 or Gene ID 480489 (SEQ ID NO:2 or 18), BCSG-3 or Gene ID
274731 (SEQ ID NO:3 or 20), BCSG-4 or Gene ID 173388 (SEQ ID NO:4)
or BCSG-5 or Clone ID 3040232, Gene ID 411152 (SEQ ID NO:5), or
levels of polynucleotides which are capable of hybridizing under
stringent conditions to the antisense sequences of SEQ ID NO: 1, 2,
3, 4, 5, 18 or 20.
[0008] Other objects, features, advantages and aspects of the
present invention will become apparent to those of skill in the art
from the following description. It should be understood, however,
that the following description and the specific examples, while
indicating preferred embodiments of the invention, are given by way
of illustration only. Various changes and modifications within the
spirit and scope of the disclosed invention will become readily
apparent to those skilled in the art from reading the following
description and from reading the other parts of the present
disclosure.
SUMMARY OF THE INVENTION
[0009] Toward these ends, and others, it is an object of the
present invention to provide BCSGs comprising a polynucleotide of
SEQ ID NO:1, 2, 3, 4, 5, 18 or 20 or a variant thereof, a protein
expressed by a polynucleotide of SEQ ID NO:1, 2, 3, 4, 5, 18 or 20
or variant thereof which expresses the protein; or a polynucleotide
which is capable of hybridizing under stringent conditions to the
antisense sequence of SEQ ID NO: 1, 2, 3, 4, 5, 18 or 20.
[0010] Further provided is a method for diagnosing the presence of
breast cancer by analyzing for changes in levels of BCSG in cells,
tissues or bodily fluids compared with levels of BCSG in preferably
the same cells, tissues, or bodily fluid type of a normal human
control, wherein a change in levels of BCSG in the patient versus
the normal human control is associated with breast cancer.
[0011] Further provided is a method of diagnosing metastatic breast
cancer in a patient having breast cancer which is not known to have
metastasized by identifying a human patient suspected of having
breast cancer that has metastasized; analyzing a sample of cells,
tissues, or bodily fluid from such patient for BCSG; comparing the
BCSG levels in such cells, tissues, or bodily fluid with levels of
BCSG in preferably the same cells, tissues, or bodily fluid type of
a normal human control, wherein an increase in BCSG levels in the
patient versus the normal human control is associated with breast
cancer which has metastasized.
[0012] Also provided by the invention is a method of staging breast
cancer in a human by identifying a human patient having breast
cancer; analyzing a sample of cells, tissues, or bodily fluid from
such patient for BCSG; comparing BCSG levels in such cells,
tissues, or bodily fluid with levels of BCSG in preferably the same
cells, tissues, or bodily fluid type of a normal human control,
wherein an increase in BCSG levels in the patient versus the normal
human control is associated with a cancer which is progressing and
a decrease in the levels of BCSG is associated with a cancer which
is regressing or in remission.
[0013] Further provided is a method of monitoring breast cancer in
a human patient for the onset of metastasis. The method comprises
identifying a human patient having breast cancer that is not known
to have metastasized; periodically analyzing cells, tissues, or
bodily fluid from such patient for BCSG; comparing the BCSG levels
in such cells, tissue, or bodily fluid with levels of BCSG in
preferably the same cells, tissues, or bodily fluid type of a
normal human control, wherein an increase in BCSG levels in the
patient versus the normal human control is associated with a cancer
which has metastasized.
[0014] Further provided is a method of monitoring the change in
stage of cancer in a human patient having breast cancer by looking
at levels of BCSG in the human patient. The method comprises
identifying a human patient having breast cancer; periodically
analyzing cells, tissues, or bodily fluid from such patient for
BCSG; comparing the BCSG levels in such cells, tissue, or bodily
fluid with levels of BCSG in preferably the same cells, tissues, or
bodily fluid type of a normal human control, wherein an increase in
BCSG levels in the patient versus the normal human control is
associated with breast cancer which is progressing and a decrease
in the levels of BCSG is associated with breast cancer which is
regressing or in remission.
[0015] Further provided are methods of designing new therapeutic
agents targeted to BCSGs for use in imaging and treating cancer.
For example, in one embodiment, therapeutic agents such as
antibodies targeted against a BCSG or fragments of such antibodies
can be used to treat, detect or image localization of a BCSG in a
patient for the purpose of detecting or diagnosing a disease or
condition. In this embodiment, an increase in the amount of labeled
antibody detected as compared to normal tissue would be indicative
of tumor metastases or growth. Such antibodies can be polyclonal,
monoclonal, or omniclonal or prepared by molecular biology
techniques. The term "antibody", as used herein and throughout the
instant specification is also meant to include aptamers and
single-stranded oligonucleotides such as those derived from an in
vitro evolution protocol referred to as SELEX and well known to
those skilled in the art. Antibodies can be labeled with a variety
of detectable labels including, but not limited to, radioisotopes
and paramagnetic metals. Therapeutics agents such as small molecule
and antibodies or fragments thereof which decrease the
concentration and/or activity of a BCSG can also be used in the
treatment of diseases characterized by overexpression of BCSG. In
these applications, the antibody can be used without or with
derivatization to a cytotoxic agent such as a radioisotope, enzyme,
toxin, drug or a prodrug.
[0016] Other objects, features, advantages and aspects of the
present invention will become apparent to those of skill in the art
from the following description. It should be understood, however,
that the following description and the specific examples, while
indicating preferred embodiments of the invention, are given by way
of illustration only. Various changes and modifications within the
spirit and scope of the disclosed invention will become readily
apparent to those skilled in the art from reading the following
description and from reading the other parts of the present
disclosure.
DESCRIPTION OF THE INVENTION
[0017] The present invention relates to diagnostic assays and
methods, both quantitative and qualitative for detecting,
diagnosing, monitoring, staging, prognosticating, in vivo imaging
and treating breast cancer by comparing levels of breast cancer
specific genes (BCSGs) with levels of BCSGs in a normal human
control. BCSG refers, among other things, to native proteins
expressed by the genes comprising the polynucleotide sequences of
BCSG-1 or Gene ID 332369 (SEQ ID NO: 1), BCSG-2 or Gene ID 480489
(SEQ ID NO:2 or 18), BCSG-3 or Gene ID 274731 (SEQ ID NO:3 or 20),
BCSG-4 or Gene ID 173388 (SEQ ID NO:4) or BCSG-5 or Clone ID
3040232, Gene ID 411152 (SEQ ID NO:5). Exemplary proteins expressed
by genes BCSG-2 and BCSG-3 are depicted herein as SEQ ID NO:19 and
SEQ ID NO:21. The genes encoding these proteins (SEQ ID NO:18 and
20) as well as the proteins (SEQ ID NO:19 and 21) have been
disclosed in GenBank as Accession No. AF016492.1 (SEQ ID NO:18),
AAC27891.1 (SEQ ID NO:19), AF183819 (SEQ ID NO:20) and AAF23614.1
(SEQ ID NO:21). By "BCSG" it is also meant herein variant
polynucleotides which, due to degeneracy in genetic coding,
comprise variations in nucleotide sequence as compared to SEQ ID
NO: 1, 2, 3, 4, 5, 18 or 20 but which still encode the same
proteins. The native protein being detected may be whole, a
breakdown product, a complex of molecules or chemically modified.
In the alternative, what is meant by BCSG as used herein, means the
native mRNAs encoded by the genes comprising BCSG-1 or Gene ID
3323C9 (SEQ ID NO: 1), BCSG-2 or Gene ID 480489 (SEQ ID NO:2 or
18), BCSG-3 or Gene ID 274731 (SEQ ID NO:3 or 20), BCSG-4 or Gene
ID 173388 (SEQ ID NO:4) or BCSG-5 or Clone ID 3040232, Gene ID
411152 (SEQ ID NO:5) or it can refer to the actual genes comprising
BCSG-1 or Gene ID 332369 (SEQ ID NO: 1), BCSG-2 or Gene ID 480489
(SEQ ID NO:2 or 18), BCSG-3 or Gene ID 274731 (SEQ ID NO:3 or 20),
BCSG-4 or Gene ID 173388 (SEQ ID NO:4) or BCSG-5 or Clone ID
3040232, Gene ID 411152 (SEQ ID NO:5) or levels of polynucleotides
which are capable of hybridizing under stringent conditions to the
antisense sequences of SEQ ID NO: 1, 2, 3, 4, 5, 18 or 20. Such
levels are preferably measured in at least one of, cells, tissues
and/or bodily fluids, including determination of normal and
abnormal levels. Thus, for instance, a diagnostic assay in
accordance with the invention for diagnosing over-expression of a
BCSG protein compared to normal control bodily fluids, cells, or
tissue samples can be used to diagnose the presence of cancers, and
in particular breast cancer. BCSGs may be measured alone in the
methods of the invention, or, more preferably, in combination with
other diagnostic markers for breast cancer including other BCSGs as
described herein. Other breast cancer markers, in addition to
BCSGs, useful in the present invention are known to those of skill
in the art.
Diagnostic Assays
[0018] The present invention provides methods for diagnosing the
presence of cancer, and in particular breast cancer, by analyzing
for changes in levels of BCSG in cells, tissues or bodily fluids
from a human patient compared with levels of BCSG in cells, tissues
or bodily fluids of preferably the same type from a normal human
control, wherein an increase in levels of BCSG in the patient
versus the normal human control is associated with the presence of
cancer.
[0019] Without limiting the instant invention, typically, for a
quantitative diagnostic assay a positive result indicating the
patient being tested has breast cancer is one in which cells,
tissues, or bodily fluid levels of a cancer marker, such as BCSG,
are at least two times higher, and most preferably are at least
five times higher, than in preferably the same cells, tissues, or
bodily fluid of a normal human control.
[0020] The present invention also provides a method of diagnosing
metastatic cancer, and in particular metastatic breast cancer, in a
patient having breast cancer which has not yet metastasized. In the
method of the present invention, a human cancer patient suspected
of having breast cancer which may have metastasized (but which was
not previously known to have metastasized) is identified. This is
accomplished by a variety of means known to those of skill in the
art.
[0021] In the present invention, determining the presence of BCSG
in cells, tissues, or bodily fluid, is particularly useful for
discriminating between cancers which have not metastasized and
cancers which have metastasized. Existing techniques have
difficulty discriminating between breast cancer which has
metastasized and breast cancer which has not metastasized. However,
proper treatment selection is often dependent upon such
knowledge.
[0022] In the present invention, one of the cancer marker levels
measured in cells, tissues, or bodily fluid of a human patient is
BCSG. Levels in the human patient are compared with levels of BCSG
in preferably the same cells, tissue, or bodily fluid type of a
normal human control. That is, if the cancer marker being observed
is BCSG in serum, this level is preferably compared with the level
of BCSG in serum of a normal human control. An increase in BCSG in
the human patient versus the normal human control is associated
with a cancer which has metastasized.
[0023] Without limiting the instant invention, typically, for a
quantitative diagnostic assay a positive result indicating the
cancer in the patient being tested or monitored has metastasized is
one in which cells, tissues, or bodily fluid levels of a cancer
marker, such as BCSG, are at least two times higher, and more
preferably are at least five times higher, than in preferably the
same cells, tissues, or bodily fluid of a normal human control.
[0024] Normal human control as used herein includes a human patient
without cancer and/or non cancerous samples from the patient; in
the methods for diagnosing metastasis or monitoring for metastasis,
normal human control preferably includes samples from a human
patient that is determined by reliable methods to have breast
cancer which has not metastasized, such as samples from the same
patient prior to metastasis.
Staging
[0025] The invention also provides a method of staging cancers in a
human patient.
[0026] The method comprises identifying a human patient having
breast cancer and analyzing a sample of cells, tissues, or bodily
fluid from such patient for BCSG. The measured BCSG levels are then
compared to levels of BCSG in preferably the same cells, tissues,
or bodily fluid type of a normal human control, wherein an increase
in BCSG levels in the human patient versus the normal human control
is associated with breast cancer which is progressing and a
decrease in the levels of BCSG is associated with breast cancer
which is regressing or in remission.
Monitoring
[0027] Further provided is a method of monitoring breast cancer in
a human patient for the onset of metastasis. The method comprises
identifying a human patient having breast cancer that is not known
to have metastasized; periodically analyzing cells, tissues, or
bodily fluid from such patient for BCSG; and comparing the BCSG
levels in such cells, tissue, or bodily fluid with levels of BCSG
in preferably the same cells, tissues, or bodily fluid type of a
normal human control, wherein an increase in BCSG levels in the
patient versus the normal human control is associated with breast
cancer which has metastasized.
[0028] Further provided by this invention is a method of monitoring
the change in stage of breast cancer. The method comprises
identifying a human patient having breast cancer; periodically
analyzing cells, tissues, or bodily fluid from such patient for
BCSG; and comparing the BCSG levels in such cells, tissue, or
bodily fluid with levels of BCSG in preferably the same cells,
tissues, or bodily fluid type of a normal human control, wherein an
increase in BCSG levels in the patient versus the normal human
control is associated with breast cancer which is progressing in
stage and a decrease in the levels of BCSG is associated with
breast cancer which is regressing in stage or in remission.
[0029] Monitoring such patients for onset of metastasis is periodic
and preferably done on a quarterly basis. However, this may be
performed more or less frequently depending on the cancer, the
particular patient, and the stage of the cancer.
Prognostic Testing and Clinical Trial Monitoring
[0030] The methods described herein can further be utilized as
prognostic assays to identify subjects having or at risk of
developing a disease or disorder associated with increased levels
of BCSG. The present invention provides a method in which a test
sample is obtained from a human patient and BCSG is detected. The
presence of higher BCSG levels as compared to normal human controls
is diagnostic for the human patient being at risk for developing
cancer, particularly breast cancer.
[0031] The effectiveness of therapeutic agents to decrease
expression or activity of the BCSGs of the invention can also be
monitored by analyzing levels of expression of the BCSGs in a human
patient in clinical trials or in in vitro screening assays such as
in human cells. In this way, the gene expression pattern can serve
as a marker, indicative of the physiological response of the human
patient, or cells as the case may be, to the agent being
tested.
Detection of Genetic Lesions or Mutations
[0032] The methods of the present invention can also be used to
detect genetic lesions or mutations in BCSG, thereby determining if
a human with the genetic lesion is at risk for breast cancer or has
breast cancer. Genetic lesions can be detected, for example, by
ascertaining the existence of a deletion and/or addition and/or
substitution of one or more nucleotides from the BCSGs of this
invention, a chromosomal rearrangement of BCSG, aberrant
modification of BCSG (such as of the methylation pattern of the
genomic DNA), the presence of a non-wild type splicing pattern of a
mRNA transcript of BCSG, allelic loss of BCSG, and/or inappropriate
post-translational modification of BCSG protein. Methods to detect
such lesions in the BCSG of this invention are known to those of
skill in the art.
Assay Techniques
[0033] Assay techniques that can be used to determine levels of
gene expression, such as BCSG of the present invention, in a sample
derived from a human are well-known to those of skill in the art.
Such assay methods include radioimmunoassays, reverse transcriptase
PCR (RT-PCR) assays, immunohistochemistry assays, in situ
hybridization assays, competitive-binding assays, Western Blot
analyses, ELISA assays and proteomic approaches, two-dimensional
gel electrophoresis (2D electrophoresis) and non-gel based
approaches such as mass spectrometry or protein interaction
profiling. Among these, ELISAs are frequently preferred to diagnose
a gene's expressed protein in biological fluids.
[0034] An ELISA assay initially comprises preparing an antibody, if
not readily available from a commercial source, specific to BCSG,
preferably a monoclonal antibody. In addition a reporter antibody
generally is prepared which binds specifically to BCSG. The
reporter antibody is attached to a detectable reagent such as a
radioactive, fluorescent or enzymatic reagent, for example
horseradish peroxidase enzyme or alkaline phosphatase.
[0035] To carry out the ELISA, antibody specific to BCSG is
incubated on a solid support, e.g., a polystyrene dish, that binds
the antibody. Any free protein binding sites on the dish are then
covered by incubating with a non-specific protein such as bovine
serum albumin. Next, the sample to be analyzed is incubated in the
dish, during which time BCSG binds to the specific antibody
attached to the polystyrene dish. Unbound sample is washed out with
buffer. A reporter antibody specifically directed to BCSG and
linked to a detectable reagent such as horseradish peroxidase is
placed in the dish resulting in binding of the reporter antibody to
any monoclonal antibody bound to BCSG. Unattached reporter antibody
is then washed out. Reagents for peroxidase activity, including a
calorimetric substrate are then added to the dish. Immobilized
peroxidase, linked to BCSG antibodies, produces a colored reaction
product. The amount of color developed in a given time period is
proportional to the amount of BCSG protein present in the sample.
Quantitative results typically are obtained by reference to a
standard curve.
[0036] A competition assay can also be employed wherein antibodies
specific to BCSG are attached to a solid support and labeled BCSG
and a sample derived from the patient or human control are passed
over the solid support. The amount of label detected which is
attached to the solid support can be correlated to a quantity of
BCSG in the sample.
[0037] Using all or a portion of a nucleic acid sequence of a BCSG
of the present invention as a hybridization probe, nucleic acid
methods can also be used to detect BCSG mRNA as a marker for
cancer, and in particular breast cancer. Polymerase chain reaction
(PCR) and other nucleic acid methods, such as ligase chain reaction
(LCR) and nucleic acid sequence based amplification (NASABA), can
be used to detect malignant cells for diagnosis and monitoring of
various malignancies. For example, reverse-transcriptase PCR
(RT-PCR) is a powerful technique which can be used to detect the
presence of a specific mRNA population in a complex mixture of
thousands of other mRNA species. In RT-PCR, an mRNA species is
first reverse transcribed to complementary DNA (cDNA) with use of
the enzyme reverse transcriptase; the cDNA is then amplified as in
a standard PCR reaction. RT-PCR can thus reveal by amplification
the presence of a single species of mRNA. Accordingly, if the mRNA
is highly specific for the cell that produces it, RT-PCR can be
used to identify the presence of a specific type of cell.
[0038] Hybridization to clones or oligonucleotides arrayed on a
solid support (i.e., gridding) can be used to both detect the
expression of and quantitate the level of expression of that gene.
In this approach, a cDNA encoding a BCSG gene is fixed to a
substrate. The substrate may be of any suitable type including but
not limited to glass, nitrocellulose, nylon or plastic. At least a
portion of the DNA encoding the BCSG gene is attached to the
substrate and then incubated with the analyte, which may be RNA or
a complementary DNA (cDNA) copy of the RNA, isolated from the
tissue of interest. Hybridization between the substrate bound DNA
and the analyte can be detected and quantitated by several means
including but not limited to radioactive labeling or fluorescence
labeling of the analyte or a secondary molecule designed to detect
the hybrid. Quantitation of the level of gene expression can be
done by comparison of the intensity of the signal from the analyte
compared with that determined from known standards. The standards
can be obtained by in vitro transcription of the target gene,
quantitating the yield, and then using that material to generate a
standard curve.
[0039] Of the proteomic approaches, 2D electrophoresis is a
technique well known to those in the art. Isolation of individual
proteins from a sample such as serum is accomplished using
sequential separation of proteins by different characteristics
usually on polyacrylamide gels. First, proteins are separated by
size using an electric current. The current acts uniformly on all
proteins, so smaller proteins move farther on the gel than larger
proteins. The second dimension applies a current perpendicular to
the first and separates proteins not on the basis of size but on
the specific electric charge carried by each protein. Since no two
proteins with different sequences are identical on the basis of
both size and charge, the result of a 2D separation is a square gel
in which each protein occupies a unique spot. Analysis of the spots
with chemical or antibody probes, or subsequent protein
microsequencing can reveal the relative abundance of a given
protein and the identity of the proteins in the sample.
[0040] The above tests can be carried out on samples derived from a
variety cells, bodily fluids and/or tissue extracts (homogenates or
solubilized tissue) obtained from the patient including tissue
biopsy and autopsy material. Bodily fluids useful in the present
invention include blood, urine, saliva, or any other bodily
secretion or derivative thereof. Blood can include whole blood,
plasma, serum, or any derivative of blood.
In Vivo Targeting of BCSGs/Breast Cancer Therapy
[0041] Identification of BCSGs is also useful in the rational
design of new therapeutics for imaging and treating cancers, and in
particular breast cancer. For example, in one embodiment,
antibodies which specifically bind to BCSGs can be raised and used
in vivo in patients suspected of suffering from cancer. Antibodies
which specifically bind a BCSG can be injected into a patient
suspected of having cancer for diagnostic and/or therapeutic
purposes. The preparation and use of antibodies for in vivo
diagnosis is well known in the art. For example, antibody-chelators
labeled with Indium-111 have been described for use in the
radioimmunoscintographic imaging of carcinoembryonic antigen
expressing tumors (Sumerdon et al. Nucl. Med. Biol. 1990
17:247-254). In particular, these antibody-chelators have been used
in detecting tumors in patients suspected of having recurrent
colorectal cancer (Griffin et al. J. Clin. One. 1991 9:631-640).
Antibodies with paramagnetic ions as labels for use in magnetic
resonance imaging have also been described (Lauffer, R. B. Magnetic
Resonance in Medicine 1991 22:339-342). Antibodies directed against
BCSGs can be used in a similar manner. Labeled antibodies which
specifically bind a BCSG can be injected into patients suspected of
having breast cancer for the purpose of diagnosing or staging of
the disease status of the patient. The label used will be selected
in accordance with the imaging modality to be used. For example,
radioactive labels such as Indium-111, Technetium-99m or Iodine-131
can be used for planar scans or single photon emission computed
tomography (SPECT). Positron emitting labels such as Fluorine-19
can be used in positron emission tomography. Paramagnetic ions such
as Gadlinium (III) or Manganese (II) can be used in magnetic
resonance imaging (MRI). Localization of the label permits
determination of the spread of the cancer. The amount of label
within an organ or tissue also allows determination of the presence
or absence of cancer in that organ or tissue.
[0042] For patients diagnosed with cancer, and in particular breast
cancer, injection of an antibody which specifically binds a BCSG
can also have a therapeutic benefit. The antibody may exert its
therapeutic effect alone. Alternatively, the antibody can be
conjugated to a cytotoxic agent such as a drug, toxin or
radionuclide to enhance its therapeutic effect. Drug monoclonal
antibodies have been described in the art for example by Garnett
and Baldwin, Cancer Research 1986 46:2407-2412. The use of toxins
conjugated to monoclonal antibodies for the therapy of various
cancers has also been described by Pastan et al. Cell 1986
47:641-648. Yttrium-90 labeled monoclonal antibodies have been
described for maximization of dose delivered to the tumor while
limiting toxicity to normal tissues (Goodwin and Meares Cancer
Supplement 1997 80:2675-2680). Other cytotoxic radionuclides
including, but not limited to Copper-67, Iodine-131 and Rhenium-186
can also be used for labeling of antibodies against BCSG.
[0043] Antibodies which can be used in these in vivo methods
include polyclonal, monoclonal and omniclonal antibodies and
antibodies prepared via molecular biology techniques. Antibody
fragments and aptamers and single-stranded oligonucleotides such as
those derived from an in vitro evolution protocol referred to as
SELEX and well known to those skilled in the art can also be
used.
Screening Assays
[0044] The present invention also provides methods for identifying
modulators which bind to BCSG protein or have a modulatory effect
on the expression or activity of BCSG protein. Modulators which
decrease the expression or activity of BCSG protein are believed to
be useful in treating breast cancer. Such screening assays are
known to those of skill in the art and include, without limitation,
cell-based assays and cell free assays.
[0045] Small molecules predicted via computer imaging to
specifically bind to regions of BCSG can also be designed,
synthesized and tested for use in the imaging and treatment of
breast cancer. Further, libraries of molecules can be screened for
potential anticancer agents by assessing the ability of the
molecule to bind to the BCSGs identified herein. Molecules
identified in the library as being capable of binding to BCSG are
key candidates for further evaluation for use in the treatment of
breast cancer. In a preferred embodiment, these molecules will
downregulate expression and/or activity of BCSG in cells.
Adoptive Immunotherapy and Vaccines
[0046] Adoptive immunotherapy of cancer refers to a therapeutic
approach in which immune cells with an antitumor reactivity are
administered to a tumor-bearing host, with the aim that the cells
mediate either directly or indirectly, the regression of an
established tumor. Transfusion of lymphocytes, particularly T
lymphocytes, falls into this category and investigators at the
National Cancer Institute (NCI) have used autologous reinfusion of
peripheral blood lymphocytes or tumor-infiltrating lymphocytes
(TIL), T cell cultures from biopsies of subcutaneous lymph nodules,
to treat several human cancers (Rosenberg, S. A., U.S. Pat. No.
4,690,914, issued Sep. 1, 1987; Rosenberg, S. A., et al., 1988, N.
England J. Med. 319:1676-1680).
[0047] The present invention relates to compositions and methods of
adoptive immunotherapy for the prevention and/or treatment of
primary and metastatic breast cancer in humans using macrophages
sensitized to the antigenic BCSG molecules, with or without
non-covalent complexes of heat shock protein (hsp). Antigenicity or
immunogenicity of the BCSG is readily confirmed by the ability of
the BCSG protein or a fragment thereof to raise antibodies or
educate naive effector cells, which in turn lyse target cells
expressing the antigen (or epitope).
[0048] Cancer cells are, by definition, abnormal and contain
proteins which should be recognized by the immune system as foreign
since they are not present in normal tissues. However, the immune
system often seems to ignore this abnormality and fails to attack
tumors. The foreign BCSG proteins that are produced by the cancer
cells can be used to reveal their presence. The BCSG is broken into
short fragments, called tumor antigens, which are displayed on the
surface of the cell. These tumor antigens are held or presented on
the cell surface by molecules called MHC, of which there are two
types: class I and II. Tumor antigens in association with MHC class
I molecules are recognized by cytotoxic T cells while antigen-MHC
class II complexes are recognized by a second subset of T cells
called helper cells. These cells secrete cytokines which slow or
stop tumor growth and help another type of white blood cell, B
cells, to make antibodies against the tumor cells.
[0049] In adoptive immunotherapy, T cells or other antigen
presenting cells (APCs) are stimulated outside the body (ex vivo),
using the tumor specific BCSG antigen. The stimulated cells are
then reinfused into the patient where they attack the cancerous
cells. Research has shown that using both cytotoxic and helper T
cells is far more effective than using either subset alone.
Additionally, the BCSG antigen may be complexed with heat shock
proteins to stimulate the APCs as described in U.S. Pat. No.
5,985,270.
[0050] The APCs can be selected from among those antigen presenting
cells known in the art including, but not limited to, macrophages,
dendritic cells, B lymphocytes, and a combination thereof, and are
preferably macrophages. In a preferred use, wherein cells are
autologous to the individual, autologous immune cells such as
lymphocytes, macrophages or other APCs are used to circumvent the
issue of whom to select as the donor of the immune cells for
adoptive transfer. Another problem circumvented by use of
autologous immune cells is graft versus host disease which can be
fatal if unsuccessfully treated.
[0051] In adoptive immunotherapy with gene therapy, DNA of the BCSG
can be introduced into effector cells similarly as in conventional
gene therapy. This can enhance the cytotoxicity of the effector
cells to tumor cells as they have been manipulated to produce the
antigenic protein resulting in improvement of the adoptive
immunotherapy.
[0052] BCSG antigens of this invention are also useful as
components of breast cancer vaccines. The vaccine comprises an
immunogenically stimulatory amount of an BCSG antigen.
Immunogenically stimulatory amount refers to that amount of antigen
that is able to invoke the desired immune response in the recipient
for the amelioration, or treatment of breast cancer. Effective
amounts may be determined empirically by standard procedures well
known to those skilled in the art.
[0053] The BCSG antigen may be provided in any one of a number of
vaccine formulations which are designed to induce the desired type
of immune response, e.g., antibody and/or cell mediated. Such
formulations are known in the art and include, but are not limited
to, formulations such as those described in U.S. Pat. No.
5,585,103. Vaccine formulations of the present invention used to
stimulate immune responses can also include pharmaceutically
acceptable adjuvants.
EXAMPLES
[0054] The present invention is further described by the following
examples. These examples are provided solely to illustrate the
invention by reference to specific embodiments. These
exemplifications, while illustrating certain specific aspects of
the invention, do not portray the limitations or circumscribe the
scope of the disclosed invention.
Example 1
Identification of BCSGs via CLASP
[0055] Identification of BCSGs (Breast Cancer Specific Genes) was
carried out by a systematic analysis of data in the LIFESEQ Gold
(LSGold) database available from Incyte Pharmaceuticals, Palo Alto,
Calif. using the data mining Cancer Leads Automatic Search Package
(CLASP) developed by diaDexus LLC, Santa Clara Calif.
[0056] The CLASP performs the following steps:
[0057] (1) Selection of highly expressed organ specific genes based
on the abundance level of the corresponding EST in the targeted
organ versus all the other organs.
[0058] (2) Analysis of the expression level of each highly
expressed organ specific gene in normal, tumor tissue, disease
tissue and tissue libraries associated with tumor or disease.
[0059] (3) Selection of the candidates wherein component ESTs are
exclusively or more frequently found in tumor libraries.
The CLASP allows the identification of highly expressed organ and
cancer specific genes. A final manual in depth evaluation is then
performed to finalize the Organ Cancer Specific Genes (OCSGs)
selection. Table 1 provides the BCSGs of the present invention
identified using CLASP.
TABLE-US-00001 TABLE 1 BCSGs BCSG SEQ ID NO: LSGold Clone ID LSGold
Gene ID BCSG-1 1 none 332369 BCSG-2 2 or 18 none 480489 BCSG-3 3 or
20 none 274731 BCSG-4 4 none 173388 BCSG-5 5 3040232 411152
Example 2
Determination of mRNA Expression of BCSG-5
[0060] The mRNA expression level of BCSG, BCSG-5 (SEQ ID NO:5,
Clone ID 3040232, Gene ID 411152), also referred to as MAM009, in
different tissues was analyzed using Real-Time quantitative PCR.
The results presented here for BCSG-5 support the usage of CLASP as
a tool for identifying cancer diagnostic markers.
[0061] These experiments were carried out using standard
techniques, which are well known and routine to those of skill in
the art, except where otherwise described in detail. Routine
molecular biology techniques were carried out as described in
standard laboratory manuals, such as Sambrook et al., MOLECULAR
CLONING: A LABORATORY MANUAL, 2nd Ed.; Cold Spring Harbor
Laboratory Press, Cold Spring Harbor, N.Y. (1989).
[0062] Real-Time quantitative PCR with fluorescent Taqman probes is
a quantitation detection system utilizing the 5'-3' nuclease
activity of Taq DNA polymerase. The method uses an internal
fluorescent oligonucleotide probe (Taqman) labeled with a 5'
reporter dye and a downstream, 3' quencher dye. During PCR, the
5'-3' nuclease activity of Taq DNA polymerase releases the
reporter, whose fluorescence can then be detected by the laser
detector of the Model 7700 Sequence Detection System (PE Applied
Biosystems, Foster City, Calif., USA).
[0063] Amplification of an endogenous control is used to
standardize the amount of sample RNA added to the reaction and
normalize for Reverse Transcriptase (RT) efficiency. Either
cyclophilin, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or
18S ribosomal RNA (rRNA) was used as this endogenous control. To
calculate relative quantitation between all the samples studied,
the target RNA levels for one sample were used as the basis for
comparative results (calibrator). Quantitation relative to the
"calibrator" can be obtained using the standard curve method or the
comparative method (User Bulletin #2: ABI PRISM 7700 Sequence
Detection System).
[0064] The tissue distribution, and the level of the target gene
were determined for every sample in normal and cancer tissue. Total
RNA was extracted from normal tissues, cancer tissues, and from
cancers and the corresponding matched adjacent tissues.
Subsequently, first strand cDNA was prepared with reverse
transcriptase and the polymerase chain reaction was done using
primers and Taqman probe specific to each target gene. The results
were analyzed using the ABI PRISM 7700 Sequence Detector. The
absolute numbers are relative levels of expression of the target
gene in a particular tissue compared to the calibrator tissue.
[0065] Primers used for expression analysis include:
TABLE-US-00002 BCSG-5 forward: ACCCCATTTAGCCTGCCAT (SEQ ID NO: 6)
BCSG-5 reverse: ATGGGAGTATCTCATCTGCTCTCA (SEQ ID NO: 7) Q-PCR
probe: TGTTTGTTCATTCTTCAATTCCAAGGCTTT (SEQ ID NO: 8)
[0066] The absolute numbers depicted in Table 2 are relative levels
of expression of BCSG-5 in 12 normal different tissues. All the
values are compared to normal testis (calibrator). These RNA
samples are commercially available pools, originated by pooling
samples of a particular tissue from different individuals.
TABLE-US-00003 TABLE 2 Relative Levels of BCSG-5 Expression in
Pooled Samples Tissue NORMAL Brain 0.00 Heart 0.00 Kidney 0.00
Liver 0.00 Lung 0.00 Mammary gland 106.15 Muscle 0.00 Prostate 0.00
Small Intestine 0.00 Testis 1.00 Thymus 0.00 Uterus 0.00
The relative levels of expression in Table 2 show that BCSG-5 mRNA
expression is detected in the pool of normal mammary gland and in
testis but not in the other 10 normal tissue pools analyzed. The
level of expression in mammary gland is more than 100 fold higher
than in testis. These results demonstrate that BCSG-5 mRNA
expression is highly specific for mammary gland tissue and is also
found in testis. Expression in a male specific tissue is not
relevant in detecting cancer in female specific tissues.
[0067] The absolute numbers in Table 2 were obtained analyzing
pools of samples of a particular tissue from different individuals.
They can not be compared to the absolute numbers originated from
RNA obtained from tissue samples of a single individual in Table
3.
[0068] The absolute numbers depicted in Table 3 are relative levels
of expression of BCSG-5 in 78 pairs of matching samples. All the
values are compared to normal testis (calibrator). A matching pair
is formed by mRNA from the cancer sample for a particular tissue
and mRNA from the normal adjacent sample for that same tissue from
the same individual. In addition, 2 unmatched cancer samples (from
ovary) and 2 unmatched normal samples (from ovary) were also
tested.
TABLE-US-00004 TABLE 3 Relative Levels of BCSG-5 Expression in
Individual Samples Matching Sample Normal ID Tissue Cancer Adjacent
Normal MamS621 Mammary Gland 1 60.37 0.00 MamS516 Mammary Gland 2
1.97 1.09 MamS079 Mammary Gland 3 2.31 2.74 Mam517 Mammary Gland 4
3.42 2.71 Mam59X Mammary Gland 5 0.47 9.56 MamS127 Mammary Gland 6
0.00 2.22 MamB011X Mammary Gland 7 2.52 25.28 Mam522 Mammary Gland
8 109.66 2.67 Mam51DN Mammary Gland 9 11.71 169.77 Mam19DN Mammary
Gland 10 369.64 28.24 MamS123 Mammary Gland 11 0.10 1.21 MamS997
Mammary Gland 12 8.80 2.29 Mam162X Mammary Gland 13 7.67 1.08
Mam220 Mammary Gland 14 11.50 53.60 Mam699F Mammary Gland 15 0.52
3.48 Mam42DN Mammary Gland 16 1.39 3.54 Mam76DN Mammary Gland 17
300.03 84.71 MamS854 Mammary Gland 18 2.77 2.64 MamS967 Mammary
Gland 19 892.68 4.46 Mam986 Mammary Gland 20 14.40 19.27 MamS699
Mammary Gland 21 2.24 1.43 Mam355 Mammary Gland 22 223.37 0.00
MamA06X Mammary Gland 23 1220.50 2.26 MamS570 Mammary Gland 24 0.00
120.39 MamS918 Mammary Gland 25 181.43 60.30 End12XA Endometrium 1
0.00 0.00 End28XA Endometrium 2 0.00 0.00 End3AX Endometrium 3 0.00
0.00 End4XA Endometrium 4 0.00 0.00 End5XA Endometrium 5 0.00 0.00
End10479 Endometrium 6 0.00 0.00 End65RA Endometrium 7 0.00 0.00
End68X Endometrium 8 0.00 0.00 CvxNKS18 Cervix 1 0.00 0.00 CvxNKS54
Cervix 2 0.00 0.00 CvxNK23 Cervix 3 0.00 0.00 CvxNK24 Cervix 4 0.00
0.00 CvxKS52 Cervix 5 0.00 0.00 CvxKS83 Cervix 6 0.00 0.00 Utr141XO
Uterus 1 0.00 0.00 Utr135XO Uterus 2 0.00 0.00 Utr23XU Uterus 3
0.00 0.00 Utr85XU Uterus 4 0.00 0.00 LngC20X Lung 1 0.00 0.00
LngSQ56 Lung 2 0.00 0.00 Lng90X Lung 3 0.00 0.00 LngAC11 Lung 4
0.00 0.00 Pro101XB Prostate 1 0.00 0.00 Pro23B Prostate 2 0.00 0.00
Skn448S Skin 1 0.00 0.00 Skn784S Skin 2 0.00 0.00 ClnSG45 Colon 1
0.00 0.00 ClnTX01 Colon 2 0.00 0.00 ClnAS46 Colon 3 0.00 0.00
ClnAS67 Colon 4 0.00 0.00 BldTR17 Bladder 1 0.00 0.00 Bld66X
Bladder 2 0.00 0.00 Kid11XD Kidney 1 0.00 0.00 Kid5XD Kidney 2 0.00
0.00 Kid109XD Kidney 3 0.00 0.00 Liv532L Liver 1 0.00 0.00 Liv175L
Liver 2 0.00 0.00 Liv187L Liver 3 0.00 0.00 OvrG010 Ovary 1 0.00
0.00 Ovr1005O Ovary 2 0.00 Ovr1028 Ovary 3 0.00 Ovr103X Ovary 4
0.00 0.00 Ovr18GA Ovary 5 0.00 Ovr206I Ovary 6 0.00 Pan92X Pancreas
1 0.00 0.00 PanC044 Pancreas 2 0.00 0.00 SmIH89 Small Intestine 1
0.00 0.00 SmI21XA Small Intestine 2 0.00 0.00 Sto15S Stomach 1 0.00
0.00 StoAC44 Stomach 2 0.00 0.00 Sto288S Stomach 3 0.00 0.00
Sto531S Stomach 4 0.00 0.00 Thr644T Thyroid 1 0.00 0.00 Thr145T
Thyroid 2 0.00 0.00 Thr939T Thyroid 3 0.00 0.00 Tst39X Testis 1
0.00 0.00 Tst663T Testis 2 0.00 0.00 0.00 = Negative
[0069] Among 160 samples in Table 3 representing 17 different
tissues significant expression is seen only in mammary gland
tissues. These results confirm the tissue specificity results
obtained with normal samples shown in Table 2. Table 2 and Table 3
represent a combined total of 172 samples in 21 human tissue types.
One hundred and twenty samples representing 20 different tissue
types excluding mammary gland had no detectable level of BCSG-5
mRNA. Other than mammary gland, BCSG-5 is detected only in one
tissue type (testis) and then only in the pooled tissue sample
(Table 2) but not in the matched testis cancer samples (Table 3;
testis 1 and 2).
[0070] Comparisons of the level of mRNA expression in breast cancer
samples and the normal adjacent tissue from the same individuals
are shown in Table 3. BCSG-5 is expressed at higher levels in 12 of
25 (48%) cancer samples (mammary gland 1, 2, 8, 10, 12, 13, 17, 19,
21, 22, 23 and 25) compared to normal adjacent tissue.
[0071] Altogether, the high level of tissue specificity, plus the
mRNA overexpression in 48% of the mammary gland matching samples
tested are indicative of BCSG-5, and more generally BCSGs selected
by CLASP, being good diagnostic markers for breast cancer.
Example 3
Determination of mRNA Expression of BCSG-1
[0072] The mRNA expression level of BCSG, BCSG-1 (SEQ ID NO:1, Gene
ID 332369), also referred to as MAM014 were also determined in
accordance with methods as set forth in Example 2.
[0073] Real-Time quantitative PCR was done using the following
primers:
TABLE-US-00005 BCSG-1 forward: 5'GCCCATTAGCACCCAGATAAT3' (SEQ ID
NO: 9) BCSG-2 reverse: 5'GCCAACCCTTCACCTAAGAAA3' (SEQ ID NO: 10)
Q-PCR probe 5'CTTCCCACTGTACAAAGATTTTCCAGGATG3' (SEQ ID NO: 11)
[0074] The absolute numbers depicted in Table 4 are relative levels
of expression of BCSG-1 in 37 normal samples from 25 different
tissues. All the values are compared to normal kidney (calibrator).
These RNA samples are commercially available pools, originated by
pooling samples of a particular tissue from different individuals;
except for the blood samples that they are normal samples from a
single individual.
TABLE-US-00006 TABLE 4 Relative Levels of BCSG-1 Expression in
Pooled Samples Tissue NORMAL Adrenal Gland 1.09 Bladder 0.05 Brain
24.00 Cervix 3.84 Colon 0.00 Endometrium 10.41 Esophagus 0.18 Heart
0.01 Kidney 1.00 Liver 0.02 Lung 4.35 Mammary 1.19 Muscle 0.09
Ovary 23.51 Pancreas 0.86 Prostate 7.75 Rectum 0.33 Small Intestine
0.85 Spleen 17.51 Stomach 2.42 Testis 111.04 Thymus 9.95 Trachea
6.43 Uterus 0.68 Blood 1 34.42 Blood 2 0.00 Blood 3 21.19 Blood 4
25.19 Blood 5 51.09 Blood 6 1144.10 Blood 7 59.10 Blood 8 60.13
Blood 9 37.53 Blood 10 0.00 Blood 11 15.30 Blood 12 0.00 Blood 13
0.00
[0075] The relative levels of expression in Table 4 show that
BCSG-1 mRNA expression is detected in the pool of normal mammary
gland as well as in the other normal tissue analyzed.
[0076] The absolute numbers in Table 5 were obtained analyzing
pools of samples of a particular tissue from different individuals,
except for the blood samples. They can not be compared to the
absolute numbers originated from RNA obtained from tissue samples
of a single individual in Table 5.
[0077] The absolute numbers depicted in Table 5 are relative levels
of expression of BCSG-1 in 77 pairs of matching samples. All the
values are compared to normal kidney (calibrator). A matching pair
is formed by mRNA from the cancer sample for a particular tissue
and mRNA from the normal adjacent sample for that same tissue from
the same individual. In addition, 3 unmatched cancer samples (from
ovary) and 3 unmatched normal samples (from ovary) were also
tested.
TABLE-US-00007 TABLE 5 Relative Levels of BCSG-1 Expression in
Individual Samples Matching Sample Normal ID Tissue Cancer Adjacent
Normal MamS621 Mammary Gland 1 7.48 0.00 MamS516 Mammary Gland 2
0.90 0.00 Mam173M Mammary Gland 3 3.96 0.00 Mam497M Mammary Gland 4
9.71 0.00 MamS079 Mammary Gland 5 1.72 0.00 Mam517 Mammary Gland 6
8.88 3.35 Mam726M Mammary Gland 7 3.04 0.00 Mam59X Mammary Gland 8
7.01 15.73 MamS127 Mammary Gland 9 24.59 0.00 MamB011X Mammary
Gland 10 8.43 1.14 MamS22 Mammary Gland 11 14.55 0.00 Mam15DN
Mammary Gland 12 4.16 0.00 Mam51DN Mammary Gland 13 32.90 3.11
Mam976M Mammary Gland 14 6.17 0.00 Mam543M Mammary Gland 15 34.42
0.32 Mam245M Mammary Gland 16 10.82 0.00 MamS123 Mammary Gland 17
0.37 0.00 MamS997 Mammary Gland 18 0.56 0.00 Mam162X Mammary Gland
19 6.09 0.52 Mam220 Mammary Gland 20 2.08 0.58 Mam699F Mammary
Gland 21 6.75 6.36 Mam42DN Mammary Gland 22 10.16 0.00 Mam76DN
Mammary Gland 23 31.23 4.68 MamS854 Mammary Gland 24 6.11 0.00
MamS967 Mammary Gland 25 86.22 0.00 Mam986 Mammary Gland 26 13.36
9.00 MamS699 Mammary Gland 27 4.52 0.00 Mam355 Mammary Gland 28
107.38 0.00 MamA06X Mammary Gland 29 43.26 0.00 MamS570 Mammary
Gland 30 68.36 64.22 MamS918 Mammary Gland 31 2.49 0.86 Bld66X
Bladder 0.00 3.24 ClnTX01 Colon 1 0.55 0.00 ClnAS43 Colon 2 1.11
0.00 ClnAS49 Colon 3 0.69 0.60 ClnRS45 Colon 4 0.00 0.00 CvxNK24
Cervix 1 2.53 0.69 CvxNKS54 Cervix 2 1.71 0.54 CvxNK23 Cervix 3
0.34 0.00 CvxNKS81 Cervix 4 0.00 0.00 End5XA Endometrium 1 1.16
2.85 End8911 Endometrium 2 2.62 1.65 End8963 Endometrium 3 6.50
0.00 End28XA Endometrium 4 1.75 1.33 End65RA Endometrium 5 0.45
0.00 End12XA Endometrium 6 34.80 3.55 End3AX Endometrium 7 0.00
0.00 Kid11XD Kidney 1 0.94 1.42 Kid124D Kidney 2 1.35 0.00 Liv532L
Liver 1 0.33 0.00 Liv390L Liver 2 0.66 0.00 LngSQ56 Lung 1 0.00
0.00 Lng223L Lung 2 0.20 0.00 LngLC71 Lung 3 7.67 8.20 LngAC90 Lung
4 11.70 0.98 Lng75XC Lung 5 0.00 0.00 OvrA082 Ovary 1 21.33 42.96
OvrA082 Ovary 2 52.68 186.62 Ovr103X Ovary 3 44.88 17.67 Ovr1005O
Ovary 4 6.89 Ovr1028 Ovary 5 0.44 Ovr1040O Ovary 6 0.80 Ovr18GA
Ovary 7 6.63 Ovr206I Ovary 8 1.46 Ovr20GA Ovary 9 5.96 Pan92X
Pancreas 1 0.00 0.00 Pan77X Pancreas 2 0.24 0.00 Pro23B Prostate 1
0.80 0.00 Pro13XB Prostate 2 0.05 17.75 Skn448S Skin 1 0.00 0.00
Skn784S Skin 2 0.13 0.11 SmIntH89 Small Intestine 1 0.00 0.00
Sto264S Stomach 1 0.80 1.15 Sto15S Stomach 2 0.23 2.29 Sto27S
Stomach 3 1.07 1.35 Thr644T Thyroid 1 0.00 0.00 Thr143T Thyroid 2
0.58 0.00 Tst663T Testis 1 5.46 1.80 Tst647T Testis 2 1.27 5.68
Utr23XU Uterus 1 9.38 1.17 Utr85XU Uterus 2 4.36 2.17 Utr141XO
Uterus 3 0.00 0.00 Utr135XO Uterus 4 7.53 10.10 0.00 = Negative
[0078] Table 5 represents 160 samples in 17 different tissues.
Table 4 and Table 5 represent a combined total of 197 samples in 27
human tissue types. Comparisons of the level of mRNA expression in
breast cancer samples and the normal adjacent tissue from the same
individuals are shown in Table 5. BCSG-1 is expressed at higher
levels in 27 of 30 (90%) cancer samples (mammary gland 1-7, 9-20,
22-25, 27-29, and 31) compared to normal adjacent tissue.
Example 4
Determination of mRNA Expression of BCSG-2
[0079] The mRNA expression level of BCSG, BCSG-2 (SEQ ID NO:2 or
18, Gene ID 480489), also referred to as MAM013 were also
determined in accordance with methods as set forth in Example
2.
[0080] Real-Time quantitative PCR was done using the following
primers:
TABLE-US-00008 BCSG-2 forward: 5'CCTGGAGTTTTCAATTTCCTCA3' (SEQ ID
NO: 12) BCSG-2 reverse: 5'CCCCAGAGAAAACACCACAA3' (SEQ ID NO: 13)
Q-PCR probe 5'ACTCCTCCATTTCCTTAGGTAGGGGTTTG3' (SEQ ID NO: 14)
[0081] The absolute numbers depicted in Table 6 are relative levels
of expression of BCSG-2 in 37 normal samples from 25 different
tissues. All the values are compared to normal liver (calibrator).
These RNA samples are commercially available pools, originated by
pooling samples of a particular tissue from different individuals,
except for the blood samples that they are normal samples from a
single individual.
TABLE-US-00009 TABLE 6 Relative Levels of BCSG-2 Expression in
Pooled Samples Tissue NORMAL Adrenal Gland 0.00 Bladder 0.00 Brain
0.00 Cervix 0.00 Colon 0.00 Endometrium 0.33 Esophagus 0.00 Heart
0.02 Kidney 0.28 Liver 1.00 Lung 0.07 Mammary 20.39 Muscle 0.00
Ovary 0.00 Pancreas 0.05 Prostate 0.26 Rectum 0.00 Small Intestine
0.00 Spleen 0.00 Stomach 0.12 Testis 1.55 Thymus 0.55 Trachea 1.23
Uterus 0.00 Blood 1 0.00 Blood 2 0.00 Blood 3 0.00 Blood 4 0.00
Blood 5 6.17 Blood 6 0.00 Blood 7 0.00 Blood 8 0.00 Blood 9 16.97
Blood 10 0.00 Blood 11 77.98 Blood 12 0.00 Blood 13 0.00
[0082] The relative levels of expression in Table 6 show that
BCSG-2 mRNA expression is detected in the pool of normal mammary
gland. The level of expression is higher than in the other tissues
with the exception of two blood samples.
[0083] The absolute numbers in Table 6 were obtained analyzing
pools of samples of a particular tissue from different individuals,
except for the blood samples. They can not be compared to the
absolute numbers originated from RNA obtained from tissue samples
of a single individual in Table 7.
[0084] The absolute numbers depicted in Table 7 are relative levels
of expression of BCSG-2 in 76 pairs of matching samples. All the
values are compared to normal liver (calibrator). A matching pair
is formed by mRNA from the cancer sample for a particular tissue
and mRNA from the normal adjacent sample for that same tissue from
the same individual. In addition, 3 unmatched cancer samples (from
ovary) and 3 unmatched normal samples (from ovary) were also
tested.
TABLE-US-00010 TABLE 7 Relative Levels of BCSG-2 Expression in
Individual Samples Matching Sample Normal ID Tissue Cancer Adjacent
Normal MamS621 Mammary Gland 1 0.00 0.00 Mam173M Mammary Gland 2
7.21 0.00 Mam497M Mammary Gland 3 1634.92 31.12 MamS079 Mammary
Gland 4 42.56 1.39 Mam517 Mammary Gland 5 2.42 4.21 Mam726M Mammary
Gland 6 0.00 6.75 Mam59X Mammary Gland 7 0.00 16.11 MamS127 Mammary
Gland 8 5.31 0.00 MamB011X Mammary Gland 9 0.87 182.28 Mam522
Mammary Gland 10 480.47 0.18 Mam19DN Mammary Gland 11 4.79 0.22
Mam51DN Mammary Gland 12 19.49 72.76 Mam976M Mammary Gland 13 62.25
0.00 Mam543M Mammary Gland 14 103.97 0.00 Mam245M Mammary Gland 15
49.01 615.24 MamS123 Mammary Gland 16 0.42 1.27 MamS997 Mammary
Gland 17 0.24 0.66 Mam162X Mammary Gland 18 0.45 1.39 Mam220
Mammary Gland 19 0.00 0.00 Mam699F Mammary Gland 20 0.00 12.38
Mam42DN Mammary Gland 21 44.48 11.47 Mam76DN Mammary Gland 22 9.32
26.26 MamS854 Mammary Gland 23 6.50 103.61 MamS967 Mammary Gland 24
3.36 5.13 Mam986 Mammary Gland 25 7.67 65.12 MamS699 Mammary Gland
26 1.68 11.63 Mam355 Mammary Gland 27 1.32 0.00 MamA06X Mammary
Gland 28 1.73 0.26 MamS570 Mammary Gland 29 0.00 194.69 MamS918
Mammary Gland 30 0.07 0.13 Bld66X Bladder 0.00 0.00 ClnTX01 Colon 1
0.00 0.00 ClnAS43 Colon 2 0.00 0.00 ClnAS49 Colon 3 0.00 0.00
ClnRS45 Colon 4 0.00 0.01 CvxNK24 Cervix 1 0.00 0.00 CvxNKS54
Cervix 2 0.00 0.00 CvxNK23 Cervix 3 0.02 0.00 CvxNKS81 Cervix 4
0.00 0.00 End5XA Endometrium 1 0.00 0.00 End8911 Endometrium 2 0.00
0.00 End8963 Endometrium 3 0.00 0.00 End28XA Endometrium 4 0.05
0.00 End65RA Endometrium 5 0.00 0.00 End12XA Endometrium 6 0.23
0.00 End3AX Endometrium 7 0.00 0.05 Kid11XD Kidney 1 0.04 0.00
Kid124D Kidney 2 0.37 0.00 Liv532L Liver 1 0.00 2.02 Liv390L Liver
2 0.08 0.56 Lng223L Lung 1 0.00 0.00 LngLC71 Lung 2 0.00 0.00
LngSQ56 Lung 3 0.00 0.00 LngAC90 Lung 4 0.00 0.00 Lng75XC Lung 5
0.00 0.00 OvrA082 Ovary 1 0.00 0.00 OvrA082 Ovary 2 0.00 0.00
Ovr103X Ovary 3 0.07 0.00 Ovr1005O Ovary 4 1.09 Ovr1028 Ovary 5
0.00 Ovr1040O Ovary 6 0.00 Ovr18GA Ovary 7 0.00 Ovr206I Ovary 8
0.00 Ovr20GA Ovary 9 0.00 Pan92X Pancreas 1 0.00 0.00 Pan77X
Pancreas 2 1.91 1.11 Pro23B Prostate 1 0.01 0.00 Pro13XB Prostate 2
0.00 0.00 Skn448S Skin 1 0.00 0.00 Skn784S Skin 2 0.00 0.00
SmIntH89 Small Intestine 1 0.00 0.02 Sto264S Stomach 1 0.00 0.00
Sto15S Stomach 2 0.04 0.00 Sto27S Stomach 3 0.00 0.00 Thr644T
Thyroid 1 0.00 0.12 Thr143T Thyroid 2 0.03 3.73 Tst663T Testis 1
0.09 0.00 Tst647T Testis 2 0.55 0.00 Utr23XU Uterus 1 0.00 0.00
Utr85XU Uterus 2 0.00 2.85 Utr141XO Uterus 3 0.04 0.00 Utr135XO
Uterus 4 0.17 0.12 0.00 = Negative
[0085] Table 7 represents 158 samples in 17 different tissues.
Table 6 and Table 7 represent a combined total of 195 samples in 25
human tissue types. Comparisons of the level of mRNA expression in
breast cancer samples and the normal adjacent tissue from the same
individuals are shown in Table 7. BCSG-2 is expressed at higher
levels in 11 of 30 (37%) cancer samples (mammary gland 2-4, 8, 10,
11, 13, 14, 21, 27, 28) compared to normal adjacent tissue.
Example 5
Determination of mRNA Expression of BCSG-3
[0086] The mRNA expression level of BCSG, BCSG-3 (SEQ ID NO:3 or
20, Gene ID 274731), also referred to as MAM017 were also
determined in accordance with methods as set forth in Example
2.
[0087] Real-Time quantitative PCR was done using the following
primers:
TABLE-US-00011 BCSG-3 forward: 5'GAGCACTTCCTTTTGGTTTTTC3' (SEQ ID
NO: 15) BCSG-3 reverse: 5'GCCCTAGCATATTCCAGAAGTTC3' (SEQ ID NO: 16)
Q-PCR probe 5'TAGACAGTGGGCTCACATGTTCCTG (SEQ ID NO: 17)
ATAGTG3'
[0088] The absolute numbers depicted in Table 8 are relative levels
of expression of BCSG-3 in 36 normal samples from 25 different
tissues. All the values are compared to normal prostate
(calibrator). These RNA samples are commercially available pools,
originated by pooling samples of a particular tissue from different
individuals, except for the blood samples that they are normal
samples from a single individual.
TABLE-US-00012 TABLE 8 Relative Levels of BCSG-3 Expression in
Pooled Samples Tissue NORMAL Adrenal Gland 0.16 Bladder 0.02 Brain
0.12 Cervix 1.41 Colon 0.01 Endometrium 3.77 Esophagus 0.03 Heart
0.02 Kidney 0.07 Liver 0.00 Lung 0.59 Mammary 7.67 Muscle 0.08
Ovary 0.94 Pancreas 0.14 Prostate 1.00 Rectum 0.13 Small Intestine
0.05 Spleen 0.89 Stomach 0.17 Testis 0.20 Thymus 0.56 Trachea 0.39
Uterus 1.22 Blood 1 1.91 Blood 2 1.76 Blood 3 0.76 Blood 4 0.18
Blood 5 1.41 Blood 6 1.54 Blood 7 0.48 Blood 8 1.92 Blood 9 1.63
Blood 10 1.65 Blood 11 1.83 Blood 12 0.37
[0089] The relative levels of expression in Table 8 show that
BCSG-3 mRNA expression is detected in the pool of normal mammary
gland with the highest expression value.
[0090] The absolute numbers in Table 8 were obtained analyzing
pools of samples of a particular tissue from different individuals,
except for the blood samples. They can not be compared to the
absolute numbers originated from RNA obtained from tissue samples
of a single individual in Table 9.
[0091] The absolute numbers depicted in Table 9 are relative levels
of expression of BCSG-3 in 68 pairs of matching samples. All the
values are compared to normal prostate (calibrator). A matching
pair is formed by mRNA from the cancer sample for a particular
tissue and mRNA from the normal adjacent sample for that same
tissue from the same individual. In addition, 1 unmatched cancer
sample (from ovary) and 1 unmatched normal sample (from ovary) were
also tested.
TABLE-US-00013 TABLE 9 Relative Levels of BCSG-3 Expression in
Individual Samples Matching Sample Normal ID Tissue Cancer Adjacent
Normal Mam497M Mammary Gland 1 3.22 1.11 Mam173M Mammary Gland 2
1.39 17.75 Mam726M Mammary Gland 3 7.62 1.31 MamS516 Mammary Gland
4 11.08 0.10 MamS621 Mammary Gland 5 18.25 0.05 MamS079 Mammary
Gland 6 0.78 0.24 Mam19DN Mammary Gland 7 71.01 1.39 Mam522 Mammary
Gland 8 3.35 0.16 MamS127 Mammary Gland 9 48.00 0.48 Mam162X
Mammary Gland 10 0.18 0.65 MamS123 Mammary Gland 11 49.69 0.00
MamS997 Mammary Gland 12 141.53 0.48 Mam543M Mammary Gland 13 34.66
0.10 Mam976M Mammary Gland 14 0.37 0.10 Mam74DN Mammary Gland 15
35.14 4.36 MamS918 Mammary Gland 16 16.74 5.58 MamS854 Mammary
Gland 17 1.11 1.58 Mam986 Mammary Gland 18 0.58 1.14 MamS967
Mammary Gland 19 121.94 2.97 Mam355 Mammary Gland 20 11.35 0.06
MamA06X Mammary Gland 21 7.65 0.13 Bld32XK Bladder 1 0.17 0.02
Bld66X Bladder 2 0.17 0.13 BldTR17 Bladder 3 6.21 0.00 Bld46XK
Bladder 4 0.06 0.00 BldTR14 Bladder 5 0.79 0.19 ClnB56 Colon 1 0.12
0.10 ClnDC63 Colon 2 0.21 1.09 CvxKS52 Cervix 1 10.74 2.21 CvxNK24
Cervix 2 6.96 4.63 CvxKS83 Cervix 3 2.29 2.23 CvxNK23 Cervix 4 0.22
1.54 End10479 Endometrium 1 4.68 5.13 End12XA Endometrium 2 1.68
2.00 End5XA Endometrium 3 0.38 0.40 End65RA Endometrium 4 0.49 0.38
End28XA Endometrium 5 4.32 2.94 End3AX Endometrium 6 0.21 0.21
Kid6XD Kidney 1 0.06 0.16 Kid710K Kidney 2 0.03 0.10 Liv175L Liver
1 1.24 0.09 Liv187L Liver 2 0.07 0.06 Liv15XA Liver 3 0.02 0.01
Lng47XQ Lung 1 0.15 0.06 LngAC88 Lung 2 1.78 0.95 LngAC90 Lung 3
0.46 0.00 LngSQ80 Lung 4 1.91 0.35 Ovr103X Ovary 1 25.63 2.52
OvrA084 Ovary 2 7.70 3.19 OvrG010 Ovary 3 0.62 3.40 OvrG021 Ovary 4
0.09 0.45 Ovr1118 Ovary 5 0.13 Ovr32RA Ovary 6 2.81 Pan77X Pancreas
1 0.56 0.19 Pan82XP Pancreas 2 0.62 0.73 Pro109XB Prostate 1 0.00
0.10 Pro125XB Prostate 2 0.05 0.01 Skn248S Skin 1 0.94 0.02 Skn287S
Skin 2 0.36 0.05 SmIntH89 Small Intestine 1 0.12 0.04 SmInt21XA
Small Intestine 2 0.29 0.01 Sto115S Stomach 1 1.17 0.44 Sto15S
Stomach 2 0.15 0.18 StoMT54 Stomach 3 0.12 0.18 Thr590D Thyroid
3.46 3.33 Tst647T Testis 1.06 0.24 Utr141XO Uterus 1 2.86 0.51
Utr23XU Uterus 2 0.60 0.13 Utr85XU Uterus 3 12.21 1.43 Utr135XO
Uterus 4 2.98 3.93 0.00 = Negative
[0092] Table 9 represents 138 samples in 17 different tissues.
Table 8 and Table 9 represent a combined total of 174 samples in 26
human tissue types.
[0093] Comparisons of the level of mRNA expression in breast cancer
samples and the normal adjacent tissue from the same individuals
are shown in Table 8. BSCG-3 is expressed at higher levels in 17 of
21 (81%) cancer samples (mammary gland 1, 3-6, 7-9, 11-16, 19-21)
compared to normal adjacent tissue.
Sequence CWU 1
1
2111078DNAHomo sapien 1ggatgataca agagccaaga agggacattt gagttgtgtc
gcttagatag gaaagggatc 60cagggaaaat caacagtaag tgaggatgag cagcgtctct
tggttttcat tgaggataga 120gtaagagatt gagtttagat tgcaacagaa
ggaattagtt tagataccag gaagaacttc 180ctagcctgaa gatttgtcat
agtgtctgct ttctagatat ctgggaaaga tttgataata 240gttgtttgtg
aatagaaagg aggatatgat gtttttattg gccattttgc gggactcttc
300gacttcttgc tgctgtctct tgaggataca ttccaattcc atcctggcga
gatccaagtg 360cttacgtact gtctccttag ctgccttaga gtaaacgatc
atcagttcaa tggaccaaaa 420tcaccttcag ccatgtggtt tcttcatcat
catggatttc ttttggttga caaacattct 480ggctctcaga tgcaaaaagt
cacactggga aatgaactgt aagtggtgaa attagttttg 540gtatttaatt
taaaactaca ttttagtttt tctcttctct tctatgttgc aatgaatgta
600aagtatttgg gatccagtgc ttataaacct ttccttcctt tgtgcacaga
atgtaactag 660caagcccatt agcacccaga taattctatc atgttagttt
cccatcctgg aaaatctttg 720tacagtggga agttccccga tgtgtttttc
tttcttaggt gaagggttgg ctatatcact 780ttattgaatt ttgcattcct
tagactttta aaatatacta atgtattcta gtcttactct 840aaagaccttt
gatgttaaag gaatccttca tttatttcat attccctatc tcatagggcc
900acaattattt taatacagag atgattttca aaatatttta acaactggta
caggacagat 960gccagccact cagaagggat gcctgctgta aacaagcagt
atgtatggtt gtaccaatgc 1020ctattggctg aacattatgc tactttcaga
tattaaaatg gtgttccttt gaatcgtg 107821713DNAHomo sapien 2atcgcattgc
accaggatga ctctgaaatg gacttcagtt cttctgctga tacatctcca 60gttgttactt
tagctctggg agttgtggaa aagtgctggt gtgggccgca gaatacagcc
120attggatgaa tatgaagaca atcctgaaag agcttgttca gagaggtcat
gaggtgactg 180tactggcatc ttcagcttcc attctttttg atcccaatga
tgcatccact cttaaatttg 240aagtttatcc tacatcttta actaaaactg
aatttgagaa tatcatcatg caacaggtta 300agagatggtc agacattcga
aaagatagct tttggttata tttttcacaa gaacaagaaa 360tcctgtggga
attatatgac atatttagaa acttctgtaa agatgtagtt tcaaataaga
420aagttatgaa aaaactacaa gagtcaagat ttgacatcgt ttttgcagat
gctgtttttc 480cctgtggtga gctgctggct gcgctactta acatacggtt
tgtgtacagt ctccgcttta 540ctcctggcta cacaattgaa aggcacagtg
gaggactgat tttccctcct tcctacatac 600ctattgttat gtcaaaatta
agtgatcaaa tgactttcat ggagagggta aaaaatatga 660tctatgtgct
ttattttgac ttttggttcc aaatgtctga tatgaagaag tgggatcagt
720tttacagtga agttttagga agacccacta ccttatttga gacaatggga
aaagctgaca 780tatggcttat gcgaaactcc tggagttttc aatttcctca
tccattctta ccaaacgttg 840attttgttgg aggattccac tggcaaacct
gccaaacccc tacctaagga aatggaggag 900tttgtacaga gctctggaga
aaatggtgtt gtggtgtttt ctctggggtc agtgataagt 960aacatgacag
cagaaagggc caatgtaatt gcaacagccc ttgccaagat cccacaaaag
1020gttctgtgga gatttgatgg gaataaacca gatgccttag gtctcaatac
tcggctgtat 1080aagtggatac cccagaatga ccttctaggt catccaaaaa
ccagagcttt tataactcat 1140ggtggagcca atggcatcta tgaggcaatc
taccatggga tccctatggt gggcattcca 1200ttgttttggg atcaacctga
taacattgct cacatgaagg ccaagggagc agctgttaga 1260ttggacttca
acacaatgtc gagtacagac ctgctgaatg cactgaagac agtaattaat
1320gatcctttat ataaagagaa tattatgaaa ttatcaagaa ttcaacatga
tcaaccagta 1380aagcccctgg atcgagcagt cttctggatt gaatttgtca
tgccccacaa aggagccaaa 1440caccttcgag ttgcagccca tgacctcacc
tggttccagt accactcttt ggatgtgatt 1500gggtttctgc tggcctgtgt
ggcaactgtg atatttatca tcacaaagtt ttgtctgttt 1560tgtttctgga
agtttgctag aaaagggaag aagggaaaaa gagattagtt atgtctgaca
1620tttgaagctg gaaaaccaga tagataggac aacttcagtt tattccagca
agaaagaaaa 1680gattgttatg caagatttct ttcttcctgt gac
171332327DNAHomo sapienmisc_feature(924)..(924)n is a, c, g, or t
3gatggatgca tctcaaaatg tatagccaga cttgagaggt gacaattaaa gatctaaaaa
60agagaggaga ttcccccaaa caacaatatt taattttctt agtaaaaaga ataacagaat
120gcatcgtggc aatccttaag caacattatc tatgtggact gcttaaatca
gcaaaacacc 180agaagtttgg ttaacttggg caatatgaca agtattactt
tttgggcaaa actactcatt 240aagcaatttc tctagtgtgt cggacacaaa
taggttcttt atttttggca tgtatgcctt 300tttattttca ttcaattttt
tttttttctc agacagacat agtagtaacg actagcattg 360gaaaatacat
atcactattc ttggaatatt tatggtcagt ctacttttta gtagaatatt
420tttggatagc gttgacacga tagatcttat tccatacttc tttattattg
ataattttat 480tttcattttt tgctttcatt attatacata ttttggtgga
gaagaggttg ggcttttttg 540aaagagacaa aaatttatta taacactaaa
cactcctttt ttgacatatt aaagccttta 600ttccatctct caagatatat
tataaaattt atttttttaa tttaagattt ctgaattatt 660ttatcttaaa
ttgtgatttt aaacgagcta ttatggtacg gaactttttt taatgaggaa
720tttcatgatg atttaggaat tttctctctt ggaaaaggct tcccctgtga
tgaaaatgat 780gtgccagcta aaattgtgtg ccatttaaaa actgaaaata
ttttaaaatt atttgtctat 840attctaaatt gagctttgga tcaaacttta
ggccaggacc agctcatgcg ttctcattct 900tccttttctc actctttctc
tcancactca cctctgtatt cattctgttg tttgggatag 960aaaaatcata
aagagccaac ccatctcaga acgttgtgga ttgagagaga cactacatga
1020ctccaagtat atgagaaaag gacagagctc taattgataa ctctgtagtt
caaaaggaaa 1080agagtatgcc caattctctc tacatgacat attgagattt
tttttaatca acttttaaga 1140tagtgatgtt ctgttctaaa ctgttctgtt
ttagtgaagg tagattttta taaaacaagc 1200atggggattc ttttctaagg
taatattaat gagaagggaa aaaagtatct ttaacagctc 1260tttgttgaag
cctgtggtag cacattatgt ttataattgc acatgtgcac ataatctatt
1320atgatccaat gcaaatacag ctccaaaaat attaaatgta tatatatttt
aaaatgcctg 1380aggaaataca tttttcttaa taaactgaag agtctcagta
tggctattaa aataattatt 1440agcctcctgt tgtgtggctg caaaacatca
caaagtgacc ggtcttgaga cctgtgaact 1500gctgccctgt ttagtaaata
aaattaatgc atttctagag ggggaatatc tgccatccag 1560tggtggaaat
gtggagtaaa gaagctggtg gtctgcttct gtgctgtatg ccagcctttt
1620gccttaagtt gagaggaggt caactttagc tactgtcttt ggtttgagag
ccatggcnnn 1680nnnnnnnnnn nnnnnnnnnn nnnngtcgtc tttggtgagc
cagtaaggtg aaagcttgct 1740gactgtccaa ggcacaagag aaaattgagg
aattgaaatg caacctgagt atcaaactaa 1800atattctaat caaaggtagg
tactgttagg tggaattcta tcagcaggca actgcaaatg 1860agaagaagat
agaaggacgc ccgtcgggac tttggagggc agtgttattt tcccaaagaa
1920agacggccaa gggcagaggc atggattctt tgcagagcac ttccttttgg
tttttcagta 1980ctgtttcata gacagtgggc tcacatgttc ctgatagtgc
tgcagttgct tagaaagcat 2040cccagttatt gcagtaatta gaacttctgg
aatatgctag ggcagaagta tgtcaagtat 2100gtcacatgaa gaaaatgtga
aattcaagag taatccacac gtgagaaact agacaatgta 2160cattcatgtg
ttctcttgaa aggaaaggga gagctgtaag cttcactctg tcctacaccg
2220gagaaaagca ggaataactt taccgtggaa ataatgttta gcttttatgc
agagaaaatt 2280gtccttccta gagcatagag tcccaaaact caattctggt tttcccc
23274639DNAHomo sapien 4ccagaaccga gtttaggtcc aggttctcgt tctggcaaat
ctttctcctt accttcttcc 60tccacccctc cacctatgcc atgttttccc ttagccactc
cccagctcgg tggaggaaag 120gcaggcctaa ctaggtaccg tcttcccgac
tttgctcaat gatagctggg tgggtctagc 180tgggttccag ccacttgtaa
tgtgggacat ctctcacccc aactttgtag gtggagcaac 240tgctacagag
gtaaatatga ttaactttac attccatctt tcgtctgctc ccaaacttaa
300cagcaggtaa tctgcttcta gcaagtggtg aaggtaagag aagcatctgt
ataggaggca 360agagatctga gtccttttga aggcctatcc tctgctctgt
atctcaatta ctgttcttca 420tttcaattat tcttacctac tattcagttc
ccttgatctt ttcttcttgg gggctgtctt 480agggtcaggg agattgcaga
agcaccagaa ctaggagcag ccctgagaca tggggagttg 540gagctgaagg
aggaatggca ggatgaagaa ttccctaggt gaggacgtgt gagggtggct
600gggagaaggg aggggtggtc acgaatggac ggaggggat 6395779DNAHomo sapien
5gtatacattc tttattaatc attttgcttc caaccccatt tagcctgcca ttgaaatgca
60aaagtctgtt ccaaataaag ccttggaatt gaagaatgaa caaacattga gagcagatga
120gatactccca tcagaatcca aacaaaagga ctatgaagaa agttcttggg
attctgagag 180tctctgtgag actgtttcac agaaggatgt gtgtttaccc
aaggctacac atcaaaaaga 240aatagataaa ataaatggaa aattagaagg
gtctcctgtt aaagatggtc ttctgaaggc 300taactgcgga atgaaagttt
ctattccaac taaagcctta gaattgatgg acatgcaaac 360tttcaaagca
gagcctcccg agaagccatc tgccttcgag cctgccattg aaatgcaaaa
420gtctgttcca aataaagcct tggaattgaa gaatgaacaa acattgagag
cagatcagat 480gttcccttca gaatcaaaac aaaagaaggt tgaagaaaat
tcttgggatt ctgagagtct 540ccgtgagact gtttcacaga aggatgtgtg
tgtacccaag gctacacatc aaaaagaaat 600ggataaaata agtggaaaat
tagaagattc aactagccta tcaaaaatct tggatacagt 660tcattcttgt
gaaagagcaa gggaacttca aaaagatcac tgtgaacaac gtacaggaaa
720aatggaacaa atgaaaaaga agttttgtgt actgaaaaag aaactgtcag aagcaaaaa
779619DNAArtificial SequenceSynthetic 6accccattta gcctgccat
19724DNAArtificial SequenceSynthetic 7atgggagtat ctcatctgct ctca
24830DNAArtificial SequenceSynthetic 8tgtttgttca ttcttcaatt
ccaaggcttt 30921DNAArtificial SequenceSynthetic 9gcccattagc
acccagataa t 211021DNAArtificial SequenceSynthetic 10gccaaccctt
cacctaagaa a 211130DNAArtificial SequenceSynthetic 11cttcccactg
tacaaagatt ttccaggatg 301222DNAArtificial SequenceSynthetic
12cctggagttt tcaatttcct ca 221320DNAArtificial SequenceSynthetic
13ccccagagaa aacaccacaa 201429DNAArtificial SequenceSynthetic
14actcctccat ttccttaggt aggggtttg 291522DNAArtificial
SequenceSynthetic 15gagcacttcc ttttggtttt tc 221623DNAArtificial
SequenceSynthetic 16gccctagcat attccagaag ttc 231731DNAArtificial
SequenceSynthetic 17tagacagtgg gctcacatgt tcctgatagt g
31181722DNAHomo sapien 18tgcaccagga tgactctgaa atggacttca
gttcttctgc tgatacatct cagttgttac 60tttagctctg ggagttgtgg aaaagtgctg
gtgtgggccg cagaatacag ccattggatg 120aatatgaaga caatcctgaa
agagcttgtt cagagaggtc atgaggtgac tgtactggca 180tcttcagctt
ccattctttt tgatcccaat gatgcatcca ctcttaaatt tgaagtttat
240cctacatctt taactaaaac tgaatttgag aatatcatca tgcaacaggt
taagagatgg 300tcagacattc gaaaagatag cttttggtta tatttttcac
aagaacaaga aatcctgtgg 360gaattatatg acatatttag aaacttctgt
aaagatgtag tttcaaataa gaaagttatg 420aaaaaactac aagagtcaag
atttgacatc gtttttgcag atgctgtttt tccctgtggt 480gagctgctgg
ctgcgctact taacatacgg tttgtgtaca gtctccgctt tactcctggc
540tacacaattg aaaggcacag tggaggactg attttccctc cttcctacat
acctattgtt 600atgtcaaaat taagtgatca aatgactttc atggagaggg
taaaaaatat gatctatgtg 660ctttattttg acttttggtt ccaaatgtct
gatatgaaga agtgggatca gttttacagt 720gaagttttag gaagacccac
taccttattt gagacaatgg gaaaagctga catatggctt 780atgcgaaact
cctggagttt tcaatttcct catccattct taccaaacgt tgattttgtt
840ggaggattcc actgcaaacc tgccaaaccc ctacctaagg aaatggagga
gtttgtacag 900agctctggag aaaatggtgt tgtggtgttt tctctggggt
cagtgataag taacatgaca 960gcagaaaggg ccaatgtaat tgcaacagcc
cttgccaaga tcccacaaaa ggttctgtgg 1020agatttgacg ggaataaacc
agatgcctta ggtctcaata ctcggctgta caagtggata 1080ccccagaatg
accttctagg tcatccaaaa accagagctt ttataactca tggtggagcc
1140aatggcatct atgaggcaat ctaccatggg atccctatgg tgggcattcc
attgtttttt 1200gatcaacctg ataacattgc tcacatgaag gccaagggag
cagctgttag attggacttc 1260aacacaatgt cgagtacaga cctgctgaat
gcactgaaga cagtaattaa tgatccttta 1320tataaagaga atattatgaa
attatcaaga attcaacatg atcaaccagt aaagcccctg 1380gatcgagcag
tcttctggat tgaatttgtc atgccccaca aaggagccaa acaccttcga
1440gttgcagccc atgacctcac ctggttccag taccactctt tggatgtgat
tgggtttctg 1500ctggcctgtg tggcaactgt gatatttatc atcacaaagt
tttgtctgtt ttgtttctgg 1560aagtttgcta gaaaagggaa gaagggaaaa
agagattagt tatgtctgac atttgaagct 1620ggaaaaccag atagatagga
caacttcagt ttattccagc aagaaagaaa agattgttat 1680gcaagatttc
tttcttcctg tgacaaaaaa aaaaaaaaaa aa 172219529PRTHomo sapien 19Met
Thr Leu Lys Trp Thr Ser Val Leu Leu Leu Ile His Leu Ser Cys1 5 10
15Tyr Phe Ser Ser Gly Ser Cys Gly Lys Val Leu Val Trp Ala Ala Glu20
25 30Tyr Ser His Trp Met Asn Met Lys Thr Ile Leu Lys Glu Leu Val
Gln35 40 45Arg Gly His Glu Val Thr Val Leu Ala Ser Ser Ala Ser Ile
Leu Phe50 55 60Asp Pro Asn Asp Ala Ser Thr Leu Lys Phe Glu Val Tyr
Pro Thr Ser65 70 75 80Leu Thr Lys Thr Glu Phe Glu Asn Ile Ile Met
Gln Gln Val Lys Arg85 90 95Trp Ser Asp Ile Arg Lys Asp Ser Phe Trp
Leu Tyr Phe Ser Gln Glu100 105 110Gln Glu Ile Leu Trp Glu Leu Tyr
Asp Ile Phe Arg Asn Phe Cys Lys115 120 125Asp Val Val Ser Asn Lys
Lys Val Met Lys Lys Leu Gln Glu Ser Arg130 135 140Phe Asp Ile Val
Phe Ala Asp Ala Val Phe Pro Cys Gly Glu Leu Leu145 150 155 160Ala
Ala Leu Leu Asn Ile Arg Phe Val Tyr Ser Leu Arg Phe Thr Pro165 170
175Gly Tyr Thr Ile Glu Arg His Ser Gly Gly Leu Ile Phe Pro Pro
Ser180 185 190Tyr Ile Pro Ile Val Met Ser Lys Leu Ser Asp Gln Met
Thr Phe Met195 200 205Glu Arg Val Lys Asn Met Ile Tyr Val Leu Tyr
Phe Asp Phe Trp Phe210 215 220Gln Met Ser Asp Met Lys Lys Trp Asp
Gln Phe Tyr Ser Glu Val Leu225 230 235 240Gly Arg Pro Thr Thr Leu
Phe Glu Thr Met Gly Lys Ala Asp Ile Trp245 250 255Leu Met Arg Asn
Ser Trp Ser Phe Gln Phe Pro His Pro Phe Leu Pro260 265 270Asn Val
Asp Phe Val Gly Gly Phe His Cys Lys Pro Ala Lys Pro Leu275 280
285Pro Lys Glu Met Glu Glu Phe Val Gln Ser Ser Gly Glu Asn Gly
Val290 295 300Val Val Phe Ser Leu Gly Ser Val Ile Ser Asn Met Thr
Ala Glu Arg305 310 315 320Ala Asn Val Ile Ala Thr Ala Leu Ala Lys
Ile Pro Gln Lys Val Leu325 330 335Trp Arg Phe Asp Gly Asn Lys Pro
Asp Ala Leu Gly Leu Asn Thr Arg340 345 350Leu Tyr Lys Trp Ile Pro
Gln Asn Asp Leu Leu Gly His Pro Lys Thr355 360 365Arg Ala Phe Ile
Thr His Gly Gly Ala Asn Gly Ile Tyr Glu Ala Ile370 375 380Tyr His
Gly Ile Pro Met Val Gly Ile Pro Leu Phe Phe Asp Gln Pro385 390 395
400Asp Asn Ile Ala His Met Lys Ala Lys Gly Ala Ala Val Arg Leu
Asp405 410 415Phe Asn Thr Met Ser Ser Thr Asp Leu Leu Asn Ala Leu
Lys Thr Val420 425 430Ile Asn Asp Pro Leu Tyr Lys Glu Asn Ile Met
Lys Leu Ser Arg Ile435 440 445Gln His Asp Gln Pro Val Lys Pro Leu
Asp Arg Ala Val Phe Trp Ile450 455 460Glu Phe Val Met Pro His Lys
Gly Ala Lys His Leu Arg Val Ala Ala465 470 475 480His Asp Leu Thr
Trp Phe Gln Tyr His Ser Leu Asp Val Ile Gly Phe485 490 495Leu Leu
Ala Cys Val Ala Thr Val Ile Phe Ile Ile Thr Lys Phe Cys500 505
510Leu Phe Cys Phe Trp Lys Phe Ala Arg Lys Gly Lys Lys Gly Lys
Arg515 520 525Asp2010006DNAHomo sapien 20ttcctccgcg aaggctcctt
tgatattaat agtgttggtg tcttgaaact gacgtaatgc 60gcggagactg aggtcctgac
aagcgataac atttctgata aagacccgat cttactgcaa 120tctctagcgt
cctctttttt ggtgctgctg gtttctccag acctcgcgtc ctctcgattg
180ctctctcgcc ttcctatttc tttttttttt ttttaaacaa aaaacaacac
cccctcccct 240ctcccacccg gcaccgggca catccttgct ctatttcctt
tctctttctc tctctctctc 300tctctttttt aataagggtg ggggagggaa
agggggggga ggcaggaaag acctttttct 360ctcccccccg caataatcca
agatcaactc tgcaaacaac agaagacggt tcatggcttt 420ggccgccgcg
ccaccatctt tcgggctgcc gagggtgttc ttgacgatta atcaacagat
480gtacagatca gctctcaaaa tgtcttctgt gtcttctgag cgtcttctaa
gacaattgca 540ttagcctcct gctagttgac taatagaatt aataattgta
aaaagcactc taaagccaca 600tgccttatga agtcaatgct gggtatgatt
ttacaaatat ggtccggaaa aagaaccccc 660ctctgagaaa cgttgcaagt
gaaggcgagg gccagatcct ggagcctata ggtacagaaa 720gcaaggtatc
tggaaagaac aaagaattct ctgcagatca gatgtcagaa aatacggatc
780agagtgatgc tgcagaacta aatcataagg aggaacatag cttgcatgtt
caagatccat 840cttctagcag taagaaggac ttgaaaagcg cagttctgag
tgagaaggct ggcttcaatt 900atgaaagccc cagtaaggga ggaaactttc
cctcctttcc gcatgatgag gtgacagaca 960gaaatatgtt ggctttctca
tttccagctg ctgggggagt ctgtgagccc ttgaagtctc 1020cgcaaagagc
agaggcagat gaccctcaag atatggcctg caccccctca ggggactcac
1080tggagacaaa ggaagatcag aagatgtcac caaaggctac agaggaaaca
gggcaagcac 1140agagtggtca agccaattgt caaggtttga gcccagtttc
agtggcctca aaaaacccac 1200aagtgccttc agatgggggt gtaagactga
ataaatccaa aactgactta ctggtgaatg 1260acaacccaga cccggcacct
ctgtctccag agcttcagga ctttaaatgc aatatctgtg 1320gatatggtta
ctacggcaac gaccccacag atctgattaa gcacttccga aagtatcact
1380taggactgca taaccgcacc aggcaagatg ctgagctgga cagcaaaatc
ttggcccttc 1440ataacatggt gcagttcagc cattccaaag acttccagaa
ggtcaaccgt tctgtgtttt 1500ctggtgtgct gcaggacatc aattcttcaa
ggcctgtttt actaaatggg acctatgatg 1560tgcaggtgac ttcaggtgga
acattcattg gcattggacg gaaaacacca gattgccaag 1620ggaacaccaa
gtatttccgc tgtaaattct gcaatttcac ttatatgggc aactcatcca
1680ccgaattaga acaacatttt cttcagactc acccaaacaa aataaaagct
tctctcccct 1740cctctgaggt tgcaaaacct tcagagaaaa actctaacaa
gtccatccct gcacttcaat 1800ccagtgattc tggagacttg ggaaaatggc
aggacaagat aacagtcaaa gcaggagatg 1860acactcctgt tgggtactca
gtgcccataa agcccctcga ttcctctaga caaaaggtac 1920agaggccacc
agttactact ggtgtaaatt ttgtagtttc agctgtgagt catctagctc
1980acttaaactg ctagaacatt atggcaagca gcacggagca gtgcagtcag
gcggccttaa 2040tccagagtta aatgataagc tttccagggg ctctgtcatt
aatcagaatg atctagccaa 2100aagttcagaa ggagagacaa tgaccaagac
agacaagagc tcgagtgggg ctaaaaagaa 2160ggacttctcc agcaagggag
ccgaggataa tatggtaacg agctataatt gtcagttctg 2220tgacttccga
tattccaaaa gccatggccc tgatgtaatt gtagtggggc cacttctccg
2280tcattatcaa cagctccata acattcacaa gtgtaccatt aaacactgtc
cattctgtcc 2340cagaggactt tgcagcccag aaaagcacct tggagaaatt
acttatccgt ttgcttgtag 2400aaaaagtaat tgttcccact gtgcactctt
gcttctgcac
ttgtctcctg gggcggctgg 2460aagctcgcga gtcaaacatc agtgccatca
gtgttcattc accacccctg acgtagatgt 2520actcctcttt cactatgaaa
gtgtgcatga gtcccaagca tcggatgtca aacaagaagc 2580aaatcacctg
caaggatcgg atgggcagca gtctgtcaag gaaagcaaag aacactcatg
2640taccaaatgt gattttatta cccaagtgga agaagagatt tcccgacact
acaggagagc 2700acacagctgc tacaaatgcc gtcagtgcag ttttacagct
gccgatactc agtcactact 2760ggagcacttc aacactgttc actgccagga
acaggacatc actacagcca acggcgaaga 2820ggacggtcat gccatatcca
ccatcaaaga ggagcccaaa attgacttca gggtctacaa 2880tctgctaact
ccagactcta aaatgggaga gccagtttct gagagtgtgg tgaagagaga
2940gaagctggaa gagaaggacg ggctcaaaga gaaagtttgg accgagagtt
ccagtgatga 3000ccttcgcaat gtgacttgga gaggggcaga catcctgcgg
gggagtccgt catacaccca 3060agcaagcctg gggctgctga cgcctgtgtc
tggcacccaa gagcagacaa agactctaag 3120ggatagtccc aatgtggagg
ccgcccatct ggcgcgacct atttatggct tggctgtgga 3180aaccaaggga
ttcctgcagg gggcgccagc tggcggagag aagtctgggg ccctccccca
3240gcagtatcct gcatcgggag aaaacaagtc caaggatgaa tcccagtccc
tgttacggag 3300gcgtagaggc tccggtgttt tttgtgccaa ttgcctgacc
acaaagacct ctctctggcg 3360aaagaatgca aatggcggat atgtatgcaa
cgcgtgtggc ctctaccaga agcttcactc 3420gactcccagg cctttaaaca
tcattaaaca aaacaacggt gagcagatta ttaggaggag 3480aacaagaaag
cgccttaacc cagaggcact tcaggctgag cagctcaaca aacagcagag
3540gggcagcaat gaggagcaag tcaatggaag cccgttagag aggaggtcag
aagatcatct 3600aactgaaagt caccagagag aaattccact ccccagccta
agtaaatacg aagcccaggg 3660ttcattgact aaaagccatt ctgctcagca
gccagtcctg gtcagccaaa ctctggatat 3720tcacaaaagg atgcaacctt
tgcacattca gataaaaagt cctcaggaaa gtactggaga 3780tccaggaaat
agttcatccg tatctgaagg gaaaggaagt tctgagagag gcagtcctat
3840agaaaagtac atgagacctg cgaaacaccc aaattattca ccaccaggca
gccctattga 3900aaagtaccag tacccacttt ttggacttcc cttttacata
atgacttcca gagtgaagct 3960gattggctgc ggttctggag taaatataag
ctctccgttc ctgggaatcc gcactacttg 4020agtcacgtgc ctggcctacc
aaatccttgc caaaactatg tgccttatcc caccttcaat 4080ctgcctcctc
atttttcagc tgttggatca gacaatgaca ttcctctaga tttggcgatc
4140aagcattcca gacctgggcc aactgcaaac ggtgcctcca aggagaaaac
gaaggcacca 4200ccaaatgtaa aaaatgaagg tcccttgaat gtagtaaaaa
cagagaaagt tgatagaagt 4260actcaagatg aactttcaac aaaatgtgtg
cactgtggca ttgtctttct ggatgaagtg 4320atgtatgctt tgcatatgag
ttgccatggt gacagtggac ctttccagtg cagcatatgc 4380cagcatcttt
gcacggacaa atatgacttc acaacacata tccagagggg cctgcatagg
4440aacaatgcac aagtggaaaa aaatggaaaa cctaaagagt aaaaccttag
cacttagcac 4500aattaaatag aaataggttt tcttgatggg aattcaatag
cttgtaatgt cttatgaaga 4560cctattaaaa aaatacttca tagagcctgc
cttatccaac atgaaattcc cttcttttgt 4620tattctttct tttgatgagt
aggttaccaa gattaaaaag tgagataaat ggtcaatgag 4680aaagaatgga
agatggtaaa caatcacttt ttaaaacctg ttaagtcaaa accatcttgg
4740ctaatatgta ctggggaaat aatccataag agatatcacc agactagaat
taatatattt 4800ataaagaaag agaccaaaac tgtctagaat ttgaaagggt
ttacatatta ttatactaaa 4860gcagtactgg actggccatt ggaccatttg
ttccaaaacc cataaattgt tgcctaaatt 4920tataatgatc atgaaaccct
aggcagagga ggagaaattg aaggtccagg gcaatgaaag 4980aaaaatggcg
ccctctcaat ttagtcttct ctcattggcc atgtttcaga ttttgaccta
5040gaaatgcgag ctgtggttag gcttggttag agtgcagcaa gcaacatgac
agatggtggc 5100acgctgtttt tacccagccc tgcctgtaca tacacatgca
caccctctct gatatttttg 5160tcctttagat gttcaaatac tcagtagtcc
ttttgtttgc ggtttagatt cattttgtcc 5220acacatgtac ccattttaaa
aaacaatgtc ctcgatgctt ctgtagtgat ttcattttag 5280ccaggtattt
ctttcttgtg tgtgatgaac cagtatggat ttgcttttct aagcctcctg
5340ttggttacta atctcacttg gcacattata actaaaggaa tcccctcaat
tcaaaagcat 5400agatggatac aaatgtcaga ccgtgggttt aatttgttta
gaacacatgg catttcttca 5460caaggtaacc tgctgtattt atttattttc
ttttggttaa atataatttc caaactttgt 5520ggtcaggcag cgtctaaggt
tacgttacca cagactgaca gttggtatat gtaccagcca 5580atcccttcat
taaatgtata cagatttagt taagtagcat taaataggat tcttagaagt
5640atgtcctcat agaactttta atacttaagg ctttgtaaaa actatccatg
aagggaaagc 5700tcctcagcat aactgctcag ggaaataggg ctaaataact
gaacattaaa taattggtta 5760aaggtgctgt tagtcgagcc tcaatgcttg
ctacaaggat gtatgtacaa ggactgactt 5820taataatttg cattatattg
tcccaaccag tagtttattt tttgccacgg agatgtagaa 5880gatattacaa
gctactggat gcactgtcag attaacttat ttcattaaag aagttgggag
5940aacaaatagg aaaaaaaaac ttatttttct agtaaatatt aatgtattac
atttcaaata 6000atggtgcctg acatattgaa taattatttt ctacagtgta
cgtatgcaac aaagatattc 6060catcatgcat tagagtcagt tctggctctg
cctagctgtt tacatttgca aatgtagcaa 6120acaaggtaat gaagcaacta
tttctattgc agtagatatc cttttgtgtg tgtgtgtgtg 6180cattaaagtt
gtaaacggta acatgaaaca aatgaaagtt cttgctataa tggtatggaa
6240aacaagaagg aaatgaaaat atttttatgc ctacttagga aaaaaagggt
agcacttatt 6300cattccaagt actttttttt ttttaatttt taagctctta
actcacattg ttatgcttaa 6360gatgataaac atatatcctc tttttattgc
tttgtctatg tttcatatga aacatttcag 6420aaattatttt gataagtgtt
gctggaatct gcaacgctga tttttttttg cattctgtag 6480tcgcatttgc
actccatttt tacattaatt cgcagttgct ttgtatcatt gttttgtttg
6540ggttttgttt ctttttcaca gtgccgggtc ttcgtttctt aaagttggat
ggcaggtaga 6600gttcaaccag ttcgtgactg ttgtagcgaa tgaagttaaa
aaaatgtctt tctgatgttg 6660tgttgtcatt ttcatttttg catttttttg
tttgcatatt aaaaaaagag aaaagagaaa 6720gcaagagaca gaaatcagga
ctaagtcctc tgcttcagtt tcattgttaa cgggccttat 6780tctgatctca
cctgtcgcgt agctctaata ttcacataaa ctgaaataaa gaagtggaat
6840gaggagcttt gacattcaaa ttatgtgatg taatttatct tccttaggaa
ttttgatgga 6900tgcatctcaa aatgtatagc cagacttgag aggtgacaat
taaagatcta aaaaagagag 6960gagattcccc caaacaacaa tatttaattt
tcttagtaaa aagaataaca gaatgcatcg 7020tggcaatcct taagcaacat
tatctatgtg gactgcttaa atcagcaaaa caccagaagt 7080ttggttaact
tgggcaatat gacaagtatt actttttggg caaaactact cattaagcaa
7140tttctctagt gtgtcggaca caaataggtt ctttattttt ggcatgtatg
cctttttatt 7200ttcattcaat tttttttttt tctcagacag acatagtagt
atcaactagc attggaaaat 7260acatatcact attcttggaa tatttatggt
cagtctactt tttagtaaaa tatttttgga 7320tagcgttgac acgatagatc
ttattccata cttctttatt attgataatt ttattttcat 7380tttttgcttt
cattattata catattttgg tggagaagag gttgggcttt tttgaaagag
7440acaaaaattt attataacac taaacactcc ttttttgaca tattaaagcc
tttattccat 7500ctctcaagat atattataaa atttattttt ttaatttaag
atttctgaat tattttatct 7560taaattgtga ttttaaacga gctattatgg
tacggaactt tttttaatga ggaatttcat 7620gatgatttag gaattttctc
tcttggaaaa ggcttcccct gtgatgaaaa tgatgtgcca 7680gctaaaattg
tgtgccattt aaaaactgaa aatattttaa aattatttgt ctatattcta
7740aattgagctt tggatcaaac tttaggccag gaccagctca tgcgttctca
ttcttccttt 7800tctcactctt tctctcatca ctcacctctg tattcattct
gttgtttggg atagaaaaat 7860cataaagagc caacccatct cagaacgttg
tggattgaga gagacactac atgactccaa 7920gtatatgaga aaaggacaga
gctctaattg ataactctgt agttcaaaag gaaagagtat 7980gcccaattct
ctctacatga catattgaga ttttttttaa tcaactttta agatagtgat
8040gttctgttct aaactgttct gttttagtga aggtagattt ttataaaaca
agcatgggga 8100ttcttttcta aggtaatatt aatgagaagg gaaaaaagta
tctttaacag ctctttgttg 8160aagcctgtgg tagcacatta tgtttataat
tgcacatgtg cacataatct attatgatcc 8220aatgcaaata cagctccaaa
aatattaaat gtatatatat tttaaaatgc ctgaggaaat 8280acatttttct
taataaactg aagagtctca gtatggctat taaaataatt attagcctcc
8340tgttgtgtgg ctgcaaaaca tcacaaagtg accggtcttg agacctgtga
actgctgccc 8400tgtttagtaa ataaaattaa tgcatttcta gagggggaat
atctgccatc cagtggtgga 8460aatgtggagt aaagaagctg gtggtctgct
tctgtgctgt atgccagcct tttgccttaa 8520gttgagagga ggtcaacttt
agctactgtc tttggtttga gagccatggc aaaaaaaaaa 8580aaagaaaaaa
agatcaagtc gtctttggtg agccagtaag gtgaaagctt gctgactgtc
8640caaggcacaa gagaaaattg aggaattgaa atgcaacctg agtatcaaac
taaatattct 8700aatcaaaggt aggtactgtt aggtggaatt ctatcagcag
gcaactgcaa atgagaagaa 8760gatagaagga cgcccgtcgg gactttggag
ggcattgtta ttttcccaaa gaaagacggc 8820caagggcaga ggcatggatt
ctttgcagag cacttccttt tggtttttca gtactgtttc 8880atagacagtg
ggctcacatg ttcctgatag tgctgcagtt gcttagaaag catcccagtt
8940aattgcagta attagaactt ctggaatatg ctagggcaga agtatgtcaa
gtatgtcaca 9000tgaagaaaat gtgaaattca agagtaatcc acacgtgaga
aactagacaa tgtacattca 9060tgtgttctct tgaaaggaaa gggagagctg
taagcttcac tctgtcctac accggagaaa 9120agcaggaata actttaccgt
ggaaataatg tttagctttt atcagagaaa attgtccttc 9180tagagcatag
agtcccaaaa ctcaattctg gttttcccct gttttttttt tttttttttt
9240tcccaacata tgaactgcag catatcactt tttctttttg tgcctcaggt
tcctcacctg 9300taaaattgaa aaatatatgt attaataata ttattaataa
taataatggt aatgtagtac 9360ttgtttgtaa agcactttga gatccttggt
tgaaaggcac cataggagtg ccaagtatta 9420ttatgtggcc aagggggtta
tttaaactgt cagttcccaa aggccaggaa aggttggggt 9480catttttctt
aaagacgagc tgtaaatatc aactaggcag ccaatagtgt tgactatgaa
9540gatgcaaaac tattactagg ctgataaaat catagtttct taatggctac
caataaggca 9600aatatcacaa taataaacgc caaattcctt agggcggact
atttgacaac cacatggaaa 9660actttggggg aggcatgagg ggggaacatc
tcaaaatgcc aatgtaaaat ttaacttaca 9720gcaatattca ccagcagaaa
atgtctttca tatggaatga tttcatgttg ctaagaaaaa 9780gaattcaatt
tgtagtcctg atttgaatac tagaatgttg gctataatag ttctgttctt
9840acaacacatg aaattttttc gttttatttt attttgtttt catagtgcat
gttcatttct 9900actcacaaac atgttcttgg tgtatttctt atgcaaacaa
tcttcaggca gcaaagatgt 9960ctgttacatc taaacttgaa taataaagtt
ttccaccagt tacaca 10006211281PRTHomo sapien 21Met Val Arg Lys Lys
Asn Pro Pro Leu Arg Asn Val Ala Ser Glu Gly1 5 10 15Glu Gly Gln Ile
Leu Glu Pro Ile Gly Thr Glu Ser Lys Val Ser Gly20 25 30Lys Asn Lys
Glu Phe Ser Ala Asp Gln Met Ser Glu Asn Thr Asp Gln35 40 45Ser Asp
Ala Ala Glu Leu Asn His Lys Glu Glu His Ser Leu His Val50 55 60Gln
Asp Pro Ser Ser Ser Ser Lys Lys Asp Leu Lys Ser Ala Val Leu65 70 75
80Ser Glu Lys Ala Gly Phe Asn Tyr Glu Ser Pro Ser Lys Gly Gly Asn85
90 95Phe Pro Ser Phe Pro His Asp Glu Val Thr Asp Arg Asn Met Leu
Ala100 105 110Phe Ser Phe Pro Ala Ala Gly Gly Val Cys Glu Pro Leu
Lys Ser Pro115 120 125Gln Arg Ala Glu Ala Asp Asp Pro Gln Asp Met
Ala Cys Thr Pro Ser130 135 140Gly Asp Ser Leu Glu Thr Lys Glu Asp
Gln Lys Met Ser Pro Lys Ala145 150 155 160Thr Glu Glu Thr Gly Gln
Ala Gln Ser Gly Gln Ala Asn Cys Gln Gly165 170 175Leu Ser Pro Val
Ser Val Ala Ser Lys Asn Pro Gln Val Pro Ser Asp180 185 190Gly Gly
Val Arg Leu Asn Lys Ser Lys Thr Asp Leu Leu Val Asn Asp195 200
205Asn Pro Asp Pro Ala Pro Leu Ser Pro Glu Leu Gln Asp Phe Lys
Cys210 215 220Asn Ile Cys Gly Tyr Gly Tyr Tyr Gly Asn Asp Pro Thr
Asp Leu Ile225 230 235 240Lys His Phe Arg Lys Tyr His Leu Gly Leu
His Asn Arg Thr Arg Gln245 250 255Asp Ala Glu Leu Asp Ser Lys Ile
Leu Ala Leu His Asn Met Val Gln260 265 270Phe Ser His Ser Lys Asp
Phe Gln Lys Val Asn Arg Ser Val Phe Ser275 280 285Gly Val Leu Gln
Asp Ile Asn Ser Ser Arg Pro Val Leu Leu Asn Gly290 295 300Thr Tyr
Asp Val Gln Val Thr Ser Gly Gly Thr Phe Ile Gly Ile Gly305 310 315
320Arg Lys Thr Pro Asp Cys Gln Gly Asn Thr Lys Tyr Phe Arg Cys
Lys325 330 335Phe Cys Asn Phe Thr Tyr Met Gly Asn Ser Ser Thr Glu
Leu Glu Gln340 345 350His Phe Leu Gln Thr His Pro Asn Lys Ile Lys
Ala Ser Leu Pro Ser355 360 365Ser Glu Val Ala Lys Pro Ser Glu Lys
Asn Ser Asn Lys Ser Ile Pro370 375 380Ala Leu Gln Ser Ser Asp Ser
Gly Asp Leu Gly Lys Trp Gln Asp Lys385 390 395 400Ile Thr Val Lys
Ala Gly Asp Asp Thr Pro Val Gly Tyr Ser Val Pro405 410 415Ile Lys
Pro Leu Asp Ser Ser Arg Gln Asn Gly Thr Glu Ala Thr Ser420 425
430Tyr Tyr Trp Cys Lys Phe Cys Ser Phe Ser Cys Glu Ser Ser Ser
Ser435 440 445Leu Lys Leu Leu Glu His Tyr Gly Lys Gln His Gly Ala
Val Gln Ser450 455 460Gly Gly Leu Asn Pro Glu Leu Asn Asp Lys Leu
Ser Arg Gly Ser Val465 470 475 480Ile Asn Gln Asn Asp Leu Ala Lys
Ser Ser Glu Gly Glu Thr Met Thr485 490 495Lys Thr Asp Lys Ser Ser
Ser Gly Ala Lys Lys Lys Asp Phe Ser Ser500 505 510Lys Gly Ala Glu
Asp Asn Met Val Thr Ser Tyr Asn Cys Gln Phe Cys515 520 525Asp Phe
Arg Tyr Ser Lys Ser His Gly Pro Asp Val Ile Val Val Gly530 535
540Pro Leu Leu Arg His Tyr Gln Gln Leu His Asn Ile His Lys Cys
Thr545 550 555 560Ile Lys His Cys Pro Phe Cys Pro Arg Gly Leu Cys
Ser Pro Glu Lys565 570 575His Leu Gly Glu Ile Thr Tyr Pro Phe Ala
Cys Arg Lys Ser Asn Cys580 585 590Ser His Cys Ala Leu Leu Leu Leu
His Leu Ser Pro Gly Ala Ala Gly595 600 605Ser Ser Arg Val Lys His
Gln Cys His Gln Cys Ser Phe Thr Thr Pro610 615 620Asp Val Asp Val
Leu Leu Phe His Tyr Glu Ser Val His Glu Ser Gln625 630 635 640Ala
Ser Asp Val Lys Gln Glu Ala Asn His Leu Gln Gly Ser Asp Gly645 650
655Gln Gln Ser Val Lys Glu Ser Lys Glu His Ser Cys Thr Lys Cys
Asp660 665 670Phe Ile Thr Gln Val Glu Glu Glu Ile Ser Arg His Tyr
Arg Arg Ala675 680 685His Ser Cys Tyr Lys Cys Arg Gln Cys Ser Phe
Thr Ala Ala Asp Thr690 695 700Gln Ser Leu Leu Glu His Phe Asn Thr
Val His Cys Gln Glu Gln Asp705 710 715 720Ile Thr Thr Ala Asn Gly
Glu Glu Asp Gly His Ala Ile Ser Thr Ile725 730 735Lys Glu Glu Pro
Lys Ile Asp Phe Arg Val Tyr Asn Leu Leu Thr Pro740 745 750Asp Ser
Lys Met Gly Glu Pro Val Ser Glu Ser Val Val Lys Arg Glu755 760
765Lys Leu Glu Glu Lys Asp Gly Leu Lys Glu Lys Val Trp Thr Glu
Ser770 775 780Ser Ser Asp Asp Leu Arg Asn Val Thr Trp Arg Gly Ala
Asp Ile Leu785 790 795 800Arg Gly Ser Pro Ser Tyr Thr Gln Ala Ser
Leu Gly Leu Leu Thr Pro805 810 815Val Ser Gly Thr Gln Glu Gln Thr
Lys Thr Leu Arg Asp Ser Pro Asn820 825 830Val Glu Ala Ala His Leu
Ala Arg Pro Ile Tyr Gly Leu Ala Val Glu835 840 845Thr Lys Gly Phe
Leu Gln Gly Ala Pro Ala Gly Gly Glu Lys Ser Gly850 855 860Ala Leu
Pro Gln Gln Tyr Pro Ala Ser Gly Glu Asn Lys Ser Lys Asp865 870 875
880Glu Ser Gln Ser Leu Leu Arg Arg Arg Arg Gly Ser Gly Val Phe
Cys885 890 895Ala Asn Cys Leu Thr Thr Lys Thr Ser Leu Trp Arg Lys
Asn Ala Asn900 905 910Gly Gly Tyr Val Cys Asn Ala Cys Gly Leu Tyr
Gln Lys Leu His Ser915 920 925Thr Pro Arg Pro Leu Asn Ile Ile Lys
Gln Asn Asn Gly Glu Gln Ile930 935 940Ile Arg Arg Arg Thr Arg Lys
Arg Leu Asn Pro Glu Ala Leu Gln Ala945 950 955 960Glu Gln Leu Asn
Lys Gln Gln Arg Gly Ser Asn Glu Glu Gln Val Asn965 970 975Gly Ser
Pro Leu Glu Arg Arg Ser Glu Asp His Leu Thr Glu Ser His980 985
990Gln Arg Glu Ile Pro Leu Pro Ser Leu Ser Lys Tyr Glu Ala Gln
Gly995 1000 1005Ser Leu Thr Lys Ser His Ser Ala Gln Gln Pro Val Leu
Val Ser1010 1015 1020Gln Thr Leu Asp Ile His Lys Arg Met Gln Pro
Leu His Ile Gln1025 1030 1035Ile Lys Ser Pro Gln Glu Ser Thr Gly
Asp Pro Gly Asn Ser Ser1040 1045 1050Ser Val Ser Glu Gly Lys Gly
Ser Ser Glu Arg Gly Ser Pro Ile1055 1060 1065Glu Lys Tyr Met Arg
Pro Ala Lys His Pro Asn Tyr Ser Pro Pro1070 1075 1080Gly Ser Pro
Ile Glu Lys Tyr Gln Tyr Pro Leu Phe Gly Leu Pro1085 1090 1095Phe
Val His Asn Asp Phe Gln Ser Glu Ala Asp Trp Leu Arg Phe1100 1105
1110Trp Ser Lys Tyr Lys Leu Ser Val Pro Gly Asn Pro His Tyr Leu1115
1120 1125Ser His Val Pro Gly Leu Pro Asn Pro Cys Gln Asn Tyr Val
Pro1130 1135 1140Tyr Pro Thr Phe Asn Leu Pro Pro His Phe Ser Ala
Val Gly Ser1145 1150 1155Asp Asn Asp Ile Pro Leu Asp Leu Ala Ile
Lys His Ser Arg Pro1160 1165 1170Gly Pro Thr Ala Asn Gly Ala Ser
Lys Glu Lys Thr Lys Ala Pro1175 1180 1185Pro Asn Val Lys Asn Glu
Gly Pro Leu Asn Val Val Lys Thr Glu1190 1195 1200Lys Val Asp Arg
Ser Thr Gln Asp Glu Leu Ser Thr Lys Cys Val1205 1210 1215His Cys
Gly Ile Val Phe Leu Asp Glu Val Met Tyr Ala Leu His1220 1225
1230Met Ser Cys His Gly Asp Ser Gly Pro Phe Gln Cys Ser Ile Cys1235
1240 1245Gln His Leu Cys Thr Asp Lys Tyr Asp Phe Thr Thr His Ile
Gln1250 1255 1260Arg Gly Leu His Arg Asn Asn Ala Gln Val Glu Lys
Asn Gly Lys1265 1270 1275Pro Lys Glu1280
* * * * *